BEFORE THE SCIENCE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: JULY 15, 2015

2 P.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 97715`

INDEX

ITEM DESCRIPTION	PAGE NO.
1. CALL TO ORDER.	3
2. ROLL CALL.	3
3. CONSIDERATION OF CONCEPT PLAN FOR THE DISCOVERY STAGE PROGRAM ANNOUNCEMENTS.	4
4. CONSIDERATION OF CONCEPT PLAN FOR THE TRANSLATION STAGE PROGRAM ANNOUNCEMENTS.	56
5. CONSIDERATION OF CONCEPT PLAN FOR THE BRIDGES PROGRAM.	62
6. CONSIDERATION OF CONCEPT PLAN FOR THE SUMMER PROGRAM TO ACCELERATE REGENERATIV MEDICINE KNOWLEDGE (FORMERLY CREATIVITY) PRO	
7. CONSIDERATION OF AMENDMENT TO CONCEPT PLA FOR CLINICAL STAGE PROJECTS TO MODIFY CO-FUN REQUIREMENT TO ALIGN IT WITH REQUIREMENT FOR PARENT AWARD AND TO MAKE OTHER CLARIFICATION AND TECHNICAL CHANGES.	DING
8. ADJOURNMENT	85

1	JULY 15, 2015; 2 P.M.
2	
3	CHAIRMAN SHEEHY: HELLO, EVERYBODY. THIS
4	IS JEFF SHEEHY. I'M READY TO BRING, I THINK, THE
5	MEETING TO ORDER. MAYBE THE FIRST STEP WOULD BE TO
6	CALL THE ROLL. WE HAVE A QUORUM?
7	MS. BONNEVILLE: YES. JEFF SHEEHY.
8	CHAIRMAN SHEEHY: HERE.
9	MS. BONNEVILLE: OS STEWARD.
10	DR. STEWARD: HERE.
11	MS. BONNEVILLE: MICHAEL FRIEDMAN.
12	DR. FRIEDMAN: HERE.
13	MS. BONNEVILLE: BERT LUBIN. SHLOMO
14	MELMED.
15	DR. MELMED: HERE.
16	MS. BONNEVILLE: ART TORRES.
17	DR. LUBIN: THIS IS BERT.
18	MS. BONNEVILLE: OH, BERT. HI. THANK
19	YOU. DR. MELMED.
20	DR. MELMED, YES.
21	MS. BONNEVILLE: ART TORRES. JON THOMAS.
22	CHAIRMAN THOMAS: HERE.
23	MS. BONNEVILLE: KRISTINA VUORI.
24	WE HAVE A QUORUM.
25	CHAIRMAN SHEEHY: SO WE HAVE A QUORUM. SO
	3

1	FIRST I WANTED TO LET EVERYBODY KNOW WE HAVE MEMBERS
2	OF THE PUBLIC HERE IN SAN FRANCISCO. AT ANY OF THE
3	OTHER SITES DO WE HAVE MEMBERS OF THE PUBLIC
4	PRESENT?
5	DR. FRIEDMAN: YES. AT MY SITE I HAVE ONE
6	MEMBER OF THE PUBLIC PRESENT.
7	CHAIRMAN SHEEHY: GREAT. OKAY. SO SHOULD
8	WE JUST GO INTO A PRESENTATION? I THINK MAYBE THE
9	BEST WAY IS TO TAKE THESE ONE BY ONE, IF PEOPLE ARE
10	COMFORTABLE WITH THAT, AND WE'LL START WITH
11	DISCOVERY STAGE PROGRAM ANNOUNCEMENTS.
12	DR. OLSON: DR. KELLY SHEPARD WILL PRESENT
13	THE PROGRAM.
14	CHAIRMAN SHEEHY: GREAT. THANKS, DR.
15	SHEPARD. I HOPE EVERYBODY HAS THE DOCUMENTS IN
16	FRONT OF THEM. I HOPE YOU HAD AN OPPORTUNITY TO
17	LOOK THROUGH THEM BECAUSE OBVIOUSLY THE CIRM TEAM
18	HAS PUT AN ENORMOUS AMOUNT OF WORK INTO THIS. AND
19	I, FOR ONE, AM JUST BLOWN AWAY BY THE AMOUNT OF
20	EFFORT THAT'S GONE INTO THIS. IF YOU HAVE
21	QUESTIONS, ETC., AND CHANGES, THAT'S WHAT THE
22	COMMITTEE IS HERE TO DO TODAY. SO, AGAIN, THANK YOU
23	TO THE CIRM TEAM FOR THEIR WORK. DR. SHEPARD, YOU
24	READY TO TAKE US THROUGH?
25	DR. SHEPARD: THANK YOU, MR. SHEEHY. GOOD
	4
	T

1	AFTERNOON, MEMBERS OF THE SUBCOMMITTEE, MEMBERS OF
2	THE PUBLIC, AND THE CIRM TEAM. IT'S REALLY MY
3	PLEASURE TO BE HERE TODAY TO PRESENT TO YOU THE
4	CONCEPTS THAT WE'RE PROPOSING, THE NEW PHASE OF CIRM
5	2.0, THE DISCOVERY AND TRANSLATION PROGRAM.
6	I'M GOING TO BE COVERING A LOT OF MATERIAL
7	TODAY, SO I'M GOING TO BE GOING FAIRLY QUICKLY AND
8	BECAUSE OF THE HIGH LEVEL OF DETAIL, BUT ALL OF THE
9	DETAILS ASSOCIATED WITH THE THINGS I'M GOING TO BE
10	TALKING ABOUT ARE IN THE DOCUMENTS THAT ARE ATTACHED
11	TO THE AGENDA. I'LL BE HAPPY TO ANSWER ANY
12	QUESTIONS FOR CLARIFICATION THAT MAY ARISE ALONG THE
13	WAY OR AFTERWARDS.
14	SO I WANT TO BEGIN BY JUST GIVING YOU AN
15	OVERVIEW OF THE TOPICS THAT I'M GOING TO BE
16	COVERING, AND THEN WE'RE GOING TO MOVE STRAIGHT INTO
17	IT. SO THE FIRST THING I'LL BE TALKING ABOUT AFTER
18	DESCRIBING OUR MISSION IS I'M JUST GOING TO GIVE A
19	VERY BRIEF INTRODUCTION TO OUR NEW CIRM 2.0
20	DISCOVERY AND TRANSLATION CONCEPT. THEN I'M GOING
21	TO GO INTO JUST A LITTLE BIT MORE DETAIL ABOUT THE
22	DISCOVERY STAGE PROGRAMS IN PARTICULAR, INCLUDING A
23	PROPOSED IMPROVEMENT IN OUR PROCESS THAT WE THINK
24	WILL HELP US REVIEW THOSE MORE EFFECTIVELY. AND
25	THEN AFTER THAT I WILL MOVE INTO THE TRANSLATION
	_

1	STAGE PROGRAMS, FIRST A GENERAL OVERVIEW AND THEN A
2	LITTLE BIT MORE DETAIL ABOUT THOSE INDIVIDUAL
3	PROGRAMS. AND I'LL CONCLUDE BY SUMMARIZING THE
4	ENTIRE DISCOVERY AND TRANSLATION PHASE OF CIRM 2.0
5	AND WHERE IT FITS INTO THE OVERALL MISSION.
6	SO I'D LIKE TO REMIND EVERYBODY, TAKING A
7	CUE FROM CIRM, WHY WE'RE ALL HERE, AND THAT'S TO
8	ACCELERATE STEM CELL TREATMENTS TO PATIENTS WITH
9	UNMET NEEDS.
10	IN ORDER TO MOST EFFECTIVELY IMPLEMENT
11	THIS MISSION, WE'VE BEEN BUSILY WORKING ON THE CIRM
12	2.0 PROCESS, WHICH IS GOING TO INCLUDE THE SPECTRUM
13	OF PROGRAMS THAT WE WILL HOPE TO BRIDGE THE GAP OF
14	TURNING IDEAS INTO THERAPIES. WE ALREADY KNOW ABOUT
15	THE CLINICAL STAGE PROGRAM WHICH BEGAN EARLIER THIS
16	YEAR AND HAS ALREADY BEEN IMPLEMENTED SUCCESSFULLY.
17	TODAY WE'RE GOING TO BE TALKING ABOUT THE DISCOVERY,
18	THE TRANSLATIONAL COMPONENTS IN MY PRESENTATION.
19	AND AFTERWARDS MY COLLEAGUES WILL BE PRESENTING YOU
20	OUR NEW CONCEPT FOR THE EDUCATION COMPONENT.
21	SO QUITE SIMPLY, I'M GOING TO STATE THE
22	OBJECTIVE OF OUR NEW DISCOVERY AND TRANSLATION
23	PROGRAM, WHICH IS SIMPLY TO PROMOTE THE DISCOVERY OF
24	PROMISING NEW STEM CELL TECHNOLOGIES AND DRIVE THEIR
25	RAPID TRANSLATION TOWARDS IMPROVING PATIENT CARE,
	6

1	TAKING THINGS ALL THE WAY FROM THE IDEA IN THE LAB
2	TO THE PATIENT.
3	IN DEVELOPING THIS PROGRAM, THERE WERE
4	REALLY FOUR CRITICAL AREAS THAT WE THOUGHT IT WOULD
5	BE IMPORTANT TO INCLUDE TO MAKE SURE THIS PROGRAM
6	COULD WORK MOST EFFECTIVELY. AND THIS IS THE SLIDE
7	WITH THE FOUR AREAS THAT WE'RE TRYING TO IMPROVE,
8	AND I'M NOT GOING TO READ THE SMALL TEXT BECAUSE I'M
9	GOING TO VERY BRIEFLY TOUCH ON EACH ONE OF THEM IN
10	MY NEXT SLIDE.
11	FIRST, CONTINUOUS, PREDICTABLE PATHWAY.
12	SO IN THIS PROGRAM WE PROPOSE IT IS VERY IMPORTANT
13	TO LAY A CONTINUOUS TRACK OF FUNDING OPPORTUNITIES
14	ALL THE WAY FROM THE EARLIEST STAGES OF RESEARCH;
15	THAT IS, DISCOVERY TO THE PATIENT. SO DISCOVERIES
16	MUST PROGRESS THROUGH TRANSLATION AND CLINICAL
17	TESTING OR COMMERCIALIZATION. SO IN ORDER FOR A
18	TRACK TO BE CONTINUOUS, FUNDING OPPORTUNITIES
19	(INAUDIBLE). SO, FOR EXAMPLE, GRANT A, FROM THE
20	DISCOVERY PHASE OF RESEARCH, IF IT SUCCESSFULLY
21	MEETS ITS OUTCOMES, MAKES THE ENTRY POINT FOR THE
22	NEXT PHASE OF FUNDING, WHICH WOULD BE THE
23	TRANSLATIONAL PROGRAM. AND THE SAME THING IS TRUE
24	FOR THOSE PROGRAMS THAT COME THROUGH TRANSLATION.
25	THEY COULD BE READY TO BE FUNDED EITHER THROUGH CIRM

1	OR ANOTHER PROGRAM FOR THE LATER STAGE OF
2	DEVELOPMENT OR READY FOR COMMERCIALIZATION.
3	THIRD, WE WANT PRESCRIBED PROGRESS. THAT
4	IS, WHEN INDIVIDUALS PROPOSE FOR A FUNDING
5	OPPORTUNITY TO DEVELOP A PROJECT, WE WANT THEM TO BE
6	THINKING AHEAD. WE WANT THEM TO EXPECT THE OUTCOME
7	OF A SUCCESSFUL PROGRAM TO BE ABLE TO ADDRESS THAT
8	NEXT STAGE. AS REFERRED TO IN PREVIOUS MEETINGS TO
9	THE BOARD ABOUT ANALYSIS OF OUR PREVIOUS PROGRAMS
10	WHERE WHEN WE FUNDED A GRANT (INAUDIBLE),
11	SPONTANEOUSLY THOSE GRANTS ONLY PROGRESSED TO
12	TRANSLATE AND DEVELOP (INAUDIBLE). HOWEVER, WHEN WE
13	PUT OUT A SPECIFIC CALL WHERE THE INTENT WAS TO LEAD
14	TO A PRODUCT THAT WOULD TRANSLATE, THOSE (INAUDIBLE)
15	WHERE WE THINK WE CAN DO BETTER THAN THAT. SO IN
16	ONE OF THE PROGRAMS I'M GOING TO TELL YOU ABOUT
17	UNDER DISCOVERY, WE'RE ACTUALLY GOING TO PROVIDE AN
18	INCENTIVE THAT REWARD TEAMS WHO ARE ABLE TO DO WHAT
19	IT TAKES TO ENSURE THAT SUCCESSFUL OUTCOME OF THEIR
20	DISCOVERY PROGRAM DOES PROGRESS INTO TRANSLATION.
21	AGAIN, WE REFER TO IT AS A PROGRESSION EVENT. I
22	WANT YOU TO REMEMBER THAT TERM BECAUSE I'M GOING TO
23	COME BACK TO IT.
24	THIRD ELEMENT, WE WANT OUR PROGRAMS TO BE
25	TIMELY AND RESPONSIVE. SO IF AN EXCITING NEW

1	CONCEPT EMERGES IN THE FIELD, SOMETHING THAT HADN'T
2	BEEN ANTICIPATED AT THE TIME WE PUT OUT THESE
3	PROGRAM ANNOUNCEMENTS, BUT PERHAPS A PROBLEM WILL
4	ARISE IN OUR CLINICAL PROGRAMS, SO (INAUDIBLE)
5	ADDITIONAL RESOURCES BEING USED TO ADDRESS THAT
6	PROBLEM. A REALLY GOOD DISCOVERY PROGRAM WOULD
7	ALLOW OPPORTUNITIES TO RESPOND IN A TIMELY WAY
8	(INAUDIBLE) THE RESOURCES OUTSIDE OF CALIFORNIA
9	(INAUDIBLE).
10	AND THEN THE FOURTH IS MULTIPLE
11	DEVELOPMENT PATHWAYS. WE OFTEN THINK OF A
12	SUCCESSFUL STEM CELL TECHNOLOGY AS SOMETHING THAT
13	LEADS TO A THERAPY. HOWEVER, STEM CELLS HAVE
14	POTENTIAL TO LEAD TO OTHER TYPES OF PRODUCTS THAT
15	HAVE THE POSSIBILITY OF HELPING PEOPLE AND
16	ADDRESSING UNMET MEDICAL NEEDS SUCH AS DIAGNOSTICS,
17	DEVICES, AND TOOLS. SO WE WANT TO MAKE SURE WE HAVE
18	SET UP A PROGRAM THAT ENABLES SUPPORT FOR WHATEVER
19	GAP FROM A DISCOVERY GRANT MAY BE, WHETHER IT LEADS
20	TO A THERAPEUTIC OR OTHER TYPES OF TRANSLATABLE
21	PRODUCTS.
22	SO NOW I'VE GIVEN YOU A BRIEF INTRODUCTION
23	TO WHAT WE HOPE TO ACHIEVE WITH OUR NEW DISCOVERY
24	AND TRANSLATION PROGRAM. NOW I'M GOING TO JUMP
25	RIGHT INTO THE DISCOVERY STAGE PROGRAMS AND

1	INTRODUCE THE THREE NEW CONCEPTS THAT WE'VE
2	DEVELOPED.
3	DR. STEWARD: THIS IS OS. COULD I
4	INTERRUPT YOU FOR JUST A SECOND?
5	DR. SHEPARD: UH-HUH.
6	DR. STEWARD: COULD YOU ANNOUNCE WHEN
7	YOU'RE CHANGING SLIDES? I'M JUST HAVING A LITTLE
8	TROUBLE FIGURING OUT WHERE YOU ARE IN THE
9	PRESENTATION.
10	DR. SHEPARD: SORRY ABOUT THAT. SO RIGHT
11	NOW I AM ON SLIDE NO. 12. IT'S GOT THREE GREEN
12	BOXES WITH PA 15-07, 08, AND 09 ON IT.
13	DR. STEWARD: OKAY. THANK YOU.
14	CHAIRMAN SHEEHY: DOES ANYBODY HAVE ANY
15	QUESTIONS? I THINK WE WANT TO MAYBE CHOP THIS UP A
16	BIT TO GIVE PEOPLE CHANCES. DID ANYONE HAVE ANY
17	QUESTIONS SO FAR?
18	MR. TORRES: WHOEVER IS MAKING ALL THE
19	NOISE, PUT THEM ON MUTE.
20	CHAIRMAN SHEEHY: SOMEBODY IS OUTSIDE, I
21	THINK, AND WE'RE GETTING WIND.
22	SO NO QUESTIONS SO FAR. THEN I DO HAVE A
23	PROCEDURAL QUESTION THOUGH. DID YOU PUT THESE ON
24	THE AGENDA AS SEPARATE ITEMS? DO WE APPROVE THESE
25	COLLECTIVELY AND TAKE PUBLIC COMMENT THEN? SO MAYBE

1	WE'LL TAKE THE DISCOVERY STAGE PROGRAM ANNOUNCEMENT
2	FIRST AND STOP FOR QUESTIONS THERE.
3	DR. SHEPARD: OKAY.
4	THE REPORTER: THE BACKGROUND NOISE IS
5	CAUSING EVERYBODY TO BREAK UP. SO IF WE COULD
6	ACTUALLY ASK PEOPLE TO MUTE IF THEY'RE NOT SPEAKING,
7	IT WOULD HELP THE RECORD IMMENSELY.
8	CHAIRMAN SHEEHY: THERE'S SOME BACKGROUND
9	NOISE THAT'S PRETTY BAD.
10	MR. TORRES: THANK YOU.
11	DR. FRIEDMAN: JEFF, THIS IS MIKE
12	FRIEDMAN. IF I CAN JUST ASK ANOTHER SLIGHT
13	PROCEDURAL QUESTION, WHICH IS THERE ARE AT LEAST TWO
14	COMPONENTS OF ALL THE THINGS WE'RE TALKING ABOUT
15	TODAY. ONE IS THE CONCEPTUAL PLAN FOR HOW THINGS
16	WILL BE DONE AND HOW APPLICATIONS WILL BE INVITED,
17	REVIEWED, AND SO FORTH. AND THAT'S REALLY IMPORTANT
18	TO DISCUSS.
19	THE SECOND IS THE AMOUNT OF MONEY THAT IS
20	PROPOSED TO BE ALLOCATED FOR THOSE TWO THINGS. AND
21	DEPENDING ON WHAT YOUR WISH IS, WE COULD DISCUSS
22	THOSE ALL TOGETHER OR THEY COULD BE BROKEN UP
23	BECAUSE WE MIGHT THINK THAT A PROPOSED PLAN IS
24	EXTREMELY GOOD, BUT THERE MIGHT BE QUESTIONS ABOUT
25	THE AMOUNT OF MONEY, IF YOU SEE MY POINT.

1	CHAIRMAN SHEEHY: I DO. THAT SEEMS
2	REASONABLE TO BREAK THEM UP AND HAVE ONE DISCUSSION
3	ON THE CONCEPT, AND THEN WE'LL ACTUALLY LOOK AT THE
4	ALLOCATIONS AND SEE HOW PEOPLE FEEL ABOUT THAT
5	AFTERWARDS IF THAT SOUNDS REASONABLE TO EVERYBODY.
6	AND WE'LL DO THAT AT THE END OF THE PRESENTATION BY
7	DR. SHEPARD FOR EACH COMPONENT.
8	DR. SHEPARD: OKAY. SO NOW I'D LIKE TO GO
9	INTO THE INDIVIDUAL PROGRAM ANNOUNCEMENTS THAT
10	COMPRISE THE NEW DISCOVERY STAGE PROGRAM. THERE ARE
11	ACTUALLY THREE: PA 15-07, 08, AND 09. AND THESE
12	ARE THREE DIFFERENT TYPES OF AWARDS THAT WORK
13	TOGETHER TO ADDRESS THE OBJECTIVES OF THE PROGRAM AS
14	A WHOLE THAT I OUTLINED FOR YOU ON MY PREVIOUS
15	SLIDES. SO I HAVE A SLIDE ON EACH OF THESE. I'M
16	GOING TO GO INTO JUST A LITTLE BIT MORE DETAIL. BUT
17	TO GIVE YOU A GENERAL OVERVIEW BEFORE I DO THAT, PA
18	15-07, WHICH WE'VE NAMED THE INCEPTION AWARD, ARE
19	REALLY AN AWARD PROGRAM TO SUPPORT THE EXPLORATION
20	OF GREAT NEW IDEAS AND GENERATE RATIONALE FOR NEW
21	DISCOVERY.
22	THE QUEST AWARDS, WHICH ARE PA 15-08, ARE
23	SORT OF THE WORKHORSE OF THE DISCOVERY PROGRAM.
24	REMEMBER HOW I TALKED ABOUT GRANT A LEADING TO GRANT
25	B, WHICH WOULD BE TRANSLATION? GRANT A IS THE QUEST
	12

1	AWARD. SO THIS IS A PROGRAM TO FUND RESEARCH ON NEW
2	STEM CELL TECHNOLOGIES THAT WILL BE READY FOR
3	TRANSLATION BY THE END OF THE AWARD IF SUCCESSFULLY
4	ACHIEVED. THIS WILL INCLUDE AN INCENTIVE TO INSPIRE
5	THE APPLICANTS TO PROGRESS THEIR SUCCESSFUL RESEARCH
6	TO TRANSLATION, WHICH I'LL DESCRIBE FOR YOU IN A
7	MINUTE. AND IT WILL ALSO INCLUDE A LINE ITEM IN THE
8	BUDGET BY ENRICHMENT ACTIVITY FOR GRADUATE STUDENTS,
9	POSTDOCTORAL FELLOWS, AND CLINICAL FELLOWS WHO ARE
10	CONDUCTING THE WORK ON THESE AWARDS.
11	THE THIRD PROGRAM ARE THE CHALLENGE
12	AWARDS. PA 15-09 IS A VERY TARGETED CALL THAT WILL
13	BE ISSUED IN A TIMELY WAY TO ADDRESS HIGHLY SPECIFIC
14	TOPICS, EITHER EMERGING NEW CONCEPTS IN THE FIELD OR
15	CHALLENGES THAT ARISE UNEXPECTEDLY WITHIN OUR
16	PROGRAM OR OUTSIDE OF OUR PROGRAM.
17	SO FIRST OF ALL, LET ME GO INTO PA 15-07,
18	THE INCEPTION AWARDS. I'VE JUST CHANGED THE SLIDE.
19	THE TOPIC OF THE SLIDE IS INCEPTION AWARDS IN GREEN.
20	SO THE INCEPTION AWARDS, THE GOAL, AGAIN, IS TO TEST
21	A NOVEL IDEA THAT COULD LEAD TO DISCOVERY OF A
22	PROMISING NEW STEM CELL TECHNOLOGY. AS AN EXAMPLE,
23	SAY A SCIENTIST HAS DISCOVERED A NEW TRANSCRIPTION
24	FACTOR THAT THEY THINK IF THEY MANIPULATED THE
25	EXPRESSION, PERHAPS IT WILL LEAD TO THE ABILITY TO

1	PRODUCE A HEPATOCYTE WITH A PROFILE THAT HAS BEEN
2	PREVIOUSLY ABLE TO BEING ACHIEVED AND THEY WANT TO
3	TEST THIS IDEA. SO IT'S A SMALL WHAT SOME PEOPLE
4	REFER TO AS A SEED-LIKE TYPE OF AWARD. WE'RE
5	PROPOSING DIRECT PROJECT COSTS OF \$150,000. WE'RE
6	NOT SPECIFYING THE TERM OR DURATION OF THE AWARD.
7	RATHER, WE EXPECT THE APPLICANT, DEPENDING ON THE
8	PROBLEM THAT THEY WOULD LIKE TO EXPLORE, TO PROPOSE
9	THAT. AND IT SHOULD BE JUSTIFIED WITHIN THAT
10	\$150,000 BUDGET A TIMELINE THAT MAKES SENSE.
11	NOW, ALTHOUGH THESE PROJECTS ARE EXPECTED
12	TO BE RATHER EXPLORATORY AND POTENTIALLY HIGH RISK,
13	HIGH REWARD, WE DO EXPECT THE APPLICANT TO DESCRIBE
14	IN THEIR APPLICATION THEIR FORWARD VISION FOR A
15	SUCCESSFUL OUTCOME. IT'S NOT ENOUGH TO JUST SAY I
16	HAVE THIS REALLY COOL IDEA I WANT TO EXPLORE. WE
17	WANT THEM TO BE THINKING AHEAD. I TEST MY IDEA, I
18	GET AN ANSWER. WHAT ARE THE POTENTIAL STEPS I COULD
19	TAKE NEXT IF I WERE TO SEE HOW THAT ANSWER COULD
20	INFORM A PATHWAY THAT COULD EVENTUALLY HELP
21	PATIENTS?
22	NOW, WE DO EXPECT A VERY HIGH APPLICATION
23	VOLUME FOR THIS TYPE OF AWARD. AND I'M MENTIONING
24	THAT NOW BECAUSE I'M GOING TO BE TALKING ABOUT A
25	PROCESS IMPROVEMENT IN A FEW SLIDES TO ADDRESS THAT

1	TO HELP US IMPLEMENT THIS PROGRAM MORE EFFECTIVELY.
2	MR. TORRES: MR. CHAIRMAN.
3	CHAIRMAN SHEEHY: YES.
4	MR. TORRES: HOW DID YOU COME UP WITH A
5	HIGH APPLICATION VOLUME AS EXPECTED? DO YOU HAVE A
6	NUMBER?
7	DR. SHEPARD: BASED ON OUR PRIOR
8	EXPERIENCE WITH FUNDING RESEARCH IN THIS SPACE, WE
9	EXPECT PROBABLY MORE THAN 300 IN A GIVEN ROUND.
10	MR. TORRES: BUT THIS IS THE FIRST TIME
11	WE'RE DOING SEED PROJECTS OR PILOT PROJECTS, RIGHT?
12	DR. SHEPARD: IT'S THE FIRST TIME WE'RE
13	DOING THIS EXACT TYPE OF AWARD, BUT WITH OUR BASIC
14	BIOLOGY, WHICH WAS A LITTLE BIT MORE PRESCRIPTIVE,
15	WE HAD OVER 300.
16	MR. TORRES: THANK YOU.
17	DR. SHEPARD: OKAY. SO I'VE MOVED ON TO
18	THE NEXT SLIDE, WHICH IS THE THIRTEENTH SLIDE ON
19	INCEPTION AWARDS. SO THIS IS WHAT I HAD DESCRIBED
20	EARLIER AS THE WORKHORSE OF THE DISCOVERY STAGE
21	PROGRAMS. I'M SORRY. I'M DESCRIBING THE QUEST
22	AWARDS.
23	CHAIRMAN SHEEHY: WE'RE GOING ON TO A
24	DIFFERENT STAGE. CAN WE KIND OF STOP AS WE GO
25	THROUGH EACH ONE JUST TO TAKE AN OPPORTUNITY FOR
	15

1	QUESTIONS?
2	DR. SHEPARD: SURE. OKAY.
3	CHAIRMAN SHEEHY: SO DOES ANYONE HAVE ANY
4	QUESTIONS ABOUT THE INCEPTION AWARDS AT ANY OF THE
5	SITES?
6	CAN WE KIND OF REVIEW WHAT THE BUDGET OF
7	THIS IS? FIVE MILLION FOR 20 AWARDS, RIGHT?
8	DR. SHEPARD: SO IN THE CONCEPT WE
9	SUGGESTED THAT \$5 MILLION WOULD BE APPROPRIATE AND
10	WOULD FUND \$20 MILLION I'M SORRY 20 AWARDS OF
11	THIS NATURE. HOWEVER, BECAUSE WHEN WE GET TO THE
12	FUNDING ALLOCATION WHERE WE'RE GOING TO REQUEST AN
13	AMOUNT THAT WILL COVER ALL THREE OF THE DISCOVERY
14	PROGRAMS, AND THE BOARD WILL HAVE THE FLEXIBILITY TO
15	DETERMINE AND ADJUST THE NUMBERS OF HOW MANY OF EACH
16	TYPE OF AWARD THEY WOULD LIKE TO GIVE BASED ON THE
17	MERIT OF WHAT'S SUBMITTED, WHICH, SINCE THIS IS THE
18	FIRST TIME WE'RE DOING THIS PROGRAM, WE CAN'T SAY
19	FOR SURE WHAT THE DIFFERENT RATIO AND THE TYPES OF
20	AWARDS WE'LL RECEIVE AND THE MERIT OF THEM. BUT
21	WE'RE SUGGESTING THAT \$5 MILLION WOULD BE SUFFICIENT
22	TO FUND AT LEAST 20 OF THE INCEPTION-TYPE AWARDS.
23	DR. FRIEDMAN: MAY I ASK A QUESTION?
24	CHAIRMAN SHEEHY: PLEASE.
25	DR. FRIEDMAN: YOU SAY STEM CELL
	1.0
	16

1	TECHNOLOGIES, AND I THINK THAT'S REALLY VALID. I
2	THINK THAT'S GOOD, BUT I'M NOT QUITE SURE WHAT'S
3	INCLUDED IN THE TECHNOLOGY. IF IT WAS A NEW
4	MECHANISTIC EXPLORATION, I'M NOT SURE I WOULD CALL
5	THAT A TECHNOLOGY, BUT MAYBE YOU WANT TO EXCLUDE
6	THAT. I'D JUST ASK FOR CLARIFICATION ON THAT ONE
7	POINT PLEASE.
8	DR. OLSON: WE'RE USING TECHNOLOGY
9	GENERICALLY TO REFER TO AN IDEA THAT COULD LEAD TO A
10	THERAPEUTIC COULD RESULT IN A DIAGNOSTIC, A
11	THERAPEUTIC, A DEVICE. SO IT'S A HYPOTHESIS
12	TESTING. IT'S AN APPROACH. TECHNOLOGY IS AN
13	APPROACH OR A HYPOTHESIS TESTING THAT COULD LEAD TO
14	ANY OF THESE OUTPUTS.
15	DR. FRIEDMAN: THAT'S VERY HELPFUL. YOU
16	MAY WANT TO MODIFY THAT WORD JUST BECAUSE I'M NOT
17	SURE EVERYBODY WOULD SEE IT I'M FINE IF WE DEFINE
18	IT THAT WAY, BUT I'M NOT SURE EVERYBODY WOULD DEFINE
19	IT A PRIORI THAT WAY. SO THAT'S VERY HELPFUL.
20	THANK YOU.
21	DR. SHEPARD: THANK YOU VERY MUCH. WE'LL
22	TAKE A NOTE OF THAT AND THINK ABOUT PERHAPS A BETTER
23	WAY TO EXPLAIN THAT.
24	CHAIRMAN SHEEHY: SO DO WE HAVE ANY
25	ADDITIONAL QUESTIONS?

1	DR. SHEPARD: THANK YOU. SO NOW I HAVE
2	TWO SLIDES THAT I'M GOING TO USE TO EXPLAIN QUEST
3	AWARDS, SO I WILL GO THROUGH THEM AND THEN I'LL
4	PAUSE AGAIN TO GIVE A CHANCE FOR ANYBODY WHO HAS
5	QUESTIONS OR CLARIFICATIONS.
6	OKAY. SO THE QUEST AWARDS OR PA 15-08 ARE
7	WHAT I HAD DESCRIBED AS THE WORKHORSE OF THE AWARDS.
8	SO THE GOAL OF ONE OF THESE AWARDS IS, SIMPLY PUT,
9	TO DISCOVER A NOVEL CANDIDATE. THAT COULD BE A
10	CANDIDATE THERAPEUTIC, CANDIDATE DEVICE, A CANDIDATE
11	DIAGNOSTIC TEST, OR A CANDIDATE TOOL THAT CAN
12	IMMEDIATELY PROGRESS TO TRANSLATION TO ENABLE BROAD
13	USE.
14	SO THE DURATION OF THIS TYPE OF AWARD
	WOULD BE TWO YEARS OR UP TO TWO YEARS. AND WE'RE
15	WOULD BE ING YEARS OR UP TO TWO YEARS. AND WE RE
15 16	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT
16	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT
16 17	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT COSTS TO BE UP TO \$1.4 MILLION PER AWARD IF THE GOAL
16 17 18	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT COSTS TO BE UP TO \$1.4 MILLION PER AWARD IF THE GOAL IS TO DISCOVER A THERAPEUTIC CANDIDATE OR UP TO
16 17 18 19	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT COSTS TO BE UP TO \$1.4 MILLION PER AWARD IF THE GOAL IS TO DISCOVER A THERAPEUTIC CANDIDATE OR UP TO \$700,000 PER AWARD IF THE GOAL IS TO DISCOVER A
16 17 18 19 20	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT COSTS TO BE UP TO \$1.4 MILLION PER AWARD IF THE GOAL IS TO DISCOVER A THERAPEUTIC CANDIDATE OR UP TO \$700,000 PER AWARD IF THE GOAL IS TO DISCOVER A CANDIDATE TOOL, DEVICE, OR DIAGNOSTIC TEST.
16 17 18 19 20 21	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT COSTS TO BE UP TO \$1.4 MILLION PER AWARD IF THE GOAL IS TO DISCOVER A THERAPEUTIC CANDIDATE OR UP TO \$700,000 PER AWARD IF THE GOAL IS TO DISCOVER A CANDIDATE TOOL, DEVICE, OR DIAGNOSTIC TEST. I HAVE REFERRED TO A LINE ITEM IN THE
16 17 18 19 20 21	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT COSTS TO BE UP TO \$1.4 MILLION PER AWARD IF THE GOAL IS TO DISCOVER A THERAPEUTIC CANDIDATE OR UP TO \$700,000 PER AWARD IF THE GOAL IS TO DISCOVER A CANDIDATE TOOL, DEVICE, OR DIAGNOSTIC TEST. I HAVE REFERRED TO A LINE ITEM IN THE BUDGET TO SUPPORT ENRICHMENT ACTIVITIES FOR GRADUATE
16 17 18 19 20 21 22	PROPOSING THE LEVEL OF SUPPORT FOR DIRECT PROJECT COSTS TO BE UP TO \$1.4 MILLION PER AWARD IF THE GOAL IS TO DISCOVER A THERAPEUTIC CANDIDATE OR UP TO \$700,000 PER AWARD IF THE GOAL IS TO DISCOVER A CANDIDATE TOOL, DEVICE, OR DIAGNOSTIC TEST. I HAVE REFERRED TO A LINE ITEM IN THE BUDGET TO SUPPORT ENRICHMENT ACTIVITIES FOR GRADUATE STUDENTS, POSTDOCTORAL, AND CLINICAL FELLOWS ON THE

1	ENRICHMENT ACTIVITIES FOR THEM. WHAT DO I MEAN BY
2	ENRICHMENT ACTIVITIES? OPPORTUNITIES FOR
3	PERSONALIZED TRAINING OR TO TAKE A COURSE IN DRUG
4	DEVELOPMENT OR REGULATORY SCIENCE, SOMETHING TO
5	ENHANCE THAT TRAINING EXPERIENCE THAT THEY'RE
6	GAINING WHILE WORKING ON THOSE PROJECTS.
7	NOW, ON MY NEXT SLIDE I'M GOING TO DISCUSS
8	THIS A LITTLE BIT MORE. WE ARE OFFERING A NEW
9	INCENTIVE PROGRAM FOR QUEST AWARDEES WHO DO ACHIEVE
10	PROGRESSION EVENTS; THAT IS, THEY ARE SUCCESSFUL IN
11	DELIVERING THE PRODUCT OF THEIR DISCOVERY GRANT INTO
12	THE NEXT PHASE OF DEVELOPMENT, WHICH WOULD BE
13	TRANSLATION.
14	AND FOR THIS ROUND OF AWARDS, BASED ON OUR
15	OWN PAST EXPERIENCE WITH SIMILAR STAGE RESEARCH, WE
16	ALSO EXPECT A HIGH VOLUME OF APPLICATIONS.
17	CHAIRMAN SHEEHY: SO I ACTUALLY HAD A
18	QUESTION.
19	DR. SHEPARD: OKAY.
20	CHAIRMAN SHEEHY: SO I GUESS I STILL DON'T
21	UNDERSTAND THE ENRICHMENT ACTIVITIES PORTION OF THIS
22	IN BOTH THIS, THAT, AND IN THE TRANSLATION. I JUST
23	DON'T IT SEEMS ADDITIVE, AND I DON'T SEE WHAT IT
24	REALLY CONTRIBUTES TOWARDS THE DEVELOPMENT OF
25	THERAPIES. I MEAN IT'S NICE FOR THOSE STUDENTS, BUT

1	IT SEEMS LIKE A DISTRACTION.
2	DR. SHEPARD: YOU'RE CORRECT IN THAT IT
3	DOESN'T SPECIFICALLY ADD TO THE DEVELOPMENT OF THOSE
4	GRANT OUTCOMES AND THERAPIES. IT'S TO ENRICH THE
5	EXPERIENCE OF THE TRAINEE. SO THE PEOPLE WHO ARE
6	CONDUCTING THE WORK ON THESE AWARDS ARE MOSTLY
7	GRADUATE STUDENTS, POSTDOCTORAL FELLOWS. AND THEIR
8	SALARIES AND TUITION, ETC., CAN BE SUPPORTED THROUGH
9	THE GRANT. HOWEVER, THIS WOULD BE A LINE ITEM IN
10	THE BUDGET THAT IS SPECIFICALLY DEDICATED TO HELP
11	THOSE TRAINEES ATTEND A MEETING OR TAKE A
12	SPECIALIZED COURSE TO HELP THEM DO BETTER, GAIN A
13	LITTLE BIT MORE OUT OF THEIR RESEARCH TRAINING
14	EXPERIENCE. BUT YOU'RE RIGHT. IT'S NOT SOMETHING
15	THAT IS DIRECTLY ADVANCING THE THERAPEUTIC OR
16	CANDIDATE GOAL OF THE PROGRAM.
17	CHAIRMAN SHEEHY: I MEAN TO ME THIS IS
18	JUST A LITTLE TOO FUZZY OF A WAY TO GIVE OUT
19	GOVERNMENT MONEY. I MEAN IT'S \$20,000, WHICH IS NOT
20	A LOT, BUT IT ENDS UP BEING ABOUT 700,000 PER SITE,
21	SO ABOUT ONE AND A HALF MILLION A YEAR. AND I JUST
22	DON'T BEST WAY I CAN DESCRIBE IT IS KIND OF LIKE
23	WHIPPED CREAM. IT'S FAIRLY IT SEEMS TO BE FAIRLY
24	RIGOROUS. WHO GETS TO DO IT? WHAT DO THEY DO? WE
25	DON'T REVIEW THAT PORTION.

1	DR. OLSON: WE DO HAVE SOME REQUIREMENTS
2	FOR WHO IS ELIGIBLE TO GET THIS MONEY. THEY HAVE TO
3	HAVE AT LEAST 75 PERCENT EFFORT ON THE PROJECT PER
4	SE. SO THEY ARE A KEY PERSONNEL. THEY ARE A PRIME
5	CONTRIBUTOR TO THE WORK OF THE PROJECT. GIVEN THE
6	NATURE OF THE PROJECT, THE THOUGHT IS THAT THEY
7	MIGHT BE INTERESTED. IF THEY'RE WORKING ON A
8	PROJECT THAT COULD LEAD TO A NEW EYE THERAPEUTIC,
9	FOR EXAMPLE, THEY MIGHT BE INTERESTED IN
10	UNDERSTANDING WHAT IS GOING ON IN THE RETINAL
11	DISEASE SPACE. THEY MIGHT WANT TO UNDERSTAND WHAT
12	IT TAKES TO MOVE SUCH A THERAPY FORWARD.
13	TRAVEL MONEY AND ABILITY TO ATTEND
14	SPECIALIZED CONFERENCES IS USUALLY IN SHORT SUPPLY
15	AND IS NEVER NECESSARILY EARMARKED ON ONE OF THESE
16	AWARDS FOR A PERSONNEL, FOR A PERSON LIKE THAT. SO
17	THE THOUGHT REALLY IS TO PROVIDE SOME MONEY TO THOSE
18	PEOPLE WHO ARE KEY WORKERS ON THOSE PROJECTS WHO
19	MIGHT BE ABLE TO UTILIZE IT. I MEAN WE'RE CALLING
20	IT ENRICH THEIR TRAINING EXPERIENCE, AND THAT'S WHAT
21	IT IS.
22	DR. SHEPARD: AND JUST ONE MORE POINT TO
23	MAKE IS THAT THEY DON'T JUST THEY'RE NOT JUST
24	ABLE TO ASK FOR \$20,000. THAT'S A MAXIMUM. IF
25	THERE'S ONLY ONE TRAINEE ON THE PROJECT, IT WOULD BE

1	\$5,000.
2	DR. FRIEDMAN: I THINK YOU MAKE VALID
3	POINTS ABOUT THE UTILITY OF EDUCATIONAL
4	OPPORTUNITIES FOR YOUNG TRAINEES, AND I THINK THAT'S
5	REALLY VALUABLE. I'M STRUCK, THOUGH, BY THE FACT
6	THAT BOTH WITH THE PREVIOUS PROPOSAL AND WITH THIS
7	PROPOSAL YOU EXPECT A HIGH VOLUME OF APPLICATIONS
8	AND WE'RE ONLY GOING TO BE FUNDING A VERY SMALL
9	MINORITY OF THEM, SOMEWHERE BETWEEN, I DON'T KNOW,
10	5, 10, 8 PERCENT OF ALL THE PROPOSALS THAT COME IN,
11	FOR VERY MODEST AMOUNTS OF MONEY.
12	AND SO WHILE THIS IS AND OKAY THING TO DO,
13	NO ONE WOULD OBJECT TO THIS KIND OF TRAINING, AND IN
14	A CAREER WAY, IT'S REALLY NICE TO DO THAT, I'M
15	LOOKING AT THE NUMBER OF APPLICATIONS THAT CAN BE
16	FUNDED. AND I WONDER IF WE MIGHT GET GREATER VALUE
17	OVERALL TO, INSTEAD OF PUTTING SOME MONEY INTO THIS
18	PART OF THE TRAINING, THE MENTORSHIP OF THESE
19	TRAINEES, TO SPEND MORE MONEY ON THE APPLICATIONS
20	THEMSELVES. AND SO I WANT TO JUST ECHO JEFF'S
21	QUESTION, IF I MAY. THANK YOU.
22	DR. HIGGINS: THIS IS A FOLLOW-UP FOR BOTH
23	FROM THE PHONE COMMENTS AND PAT'S COMMENTS. IT
24	SEEMS LIKE THIS IS SORT OF A THIRD LEG OF THE
25	EDUCATION PORTION OF THE GRANT. THIS IS POST-DOC

1	VERSUS UNDERGRADUATES VERSUS HIGH SCHOOL STUDENTS.
2	SO WE BELIEVE IN THIS. WE BELIEVE AS AN INSTITUTION
3	IN THE EDUCATION OF UP AND COMING SCIENTISTS. SO IT
4	SEEMS TO ME LIKE IT'S APPROPRIATE FOR US TO BE
5	FUNDING THIS. IT'S JUST A QUESTION OF WHERE THE
6	FUNDING SHOULD GO. AND I WOULD PROPOSE, IF WE TAKE
7	IT OUT OF HERE, DON'T DROP IT. PUT IT INTO
8	SOMETHING LIKE THE BRIDGES PORTION OF THAT WHERE
9	THERE'S A POSTDOCTORAL PROGRAM. SO I WOULD PROPOSE
10	THAT IT'S IMPORTANT
11	CHAIRMAN SHEEHY: WE HAD A TRAINING
12	PROGRAM, I GUESS, AND THAT'S WHY I KIND OF
13	THOUGHT THAT WE MADE THAT DECISION. I STILL I
14	MEAN THIS IS JUST NOT RIGOROUS ENOUGH FOR ME TO FEEL
15	SUPPORTIVE OF. I JUST WE'RE JUST PUTTING A BOLUS
16	OF MONEY OUT THERE THAT PEOPLE CAN USE. THERE IS
17	TRAVEL MONEY. THEY HAD THE ABILITY TO PUT TRAVEL
18	MONEY INTO THEIR BUDGETS WHEN THEY SUBMIT THEM AND
19	THEY FREQUENTLY DO. I JUST HAVE A HARD TIME SEEING
20	HOW THIS IS I'M WITH DR. FRIEDMAN. I WOULD
21	RATHER HAVE ONE OR TWO OR THREE MORE GRANTS PER
22	CYCLE THAN HAVE THIS PARTICULAR ASPECT OF IT.
23	DR. STEWARD: IF I COULD JUST MAYBE
24	AMPLIFY OR ADD TO OR SOMETHING. I DO THINK THAT
25	THERE COULD BE VALUE TO THIS, AND THE VALUE WOULD

1	COME FROM ATTENDING EDUCATIONAL KINDS OF THINGS,
2	CONFERENCES, WHATEVER, THAT REALLY ADVANCED THE
3	PROJECT. THAT WOULD BE AND EASY WAY TO ACCOMPLISH
4	THE SAME GOAL, BUT STILL HAVE IT DIRECTED TOWARD THE
5	END STAGE THAT WAS REALLY THE REASON THE GRANT WAS
6	FUNDED IN THE FIRST PLACE.
7	CHAIRMAN SHEEHY: OS, I'M NOT SURE THE
8	GOAL OF THIS IS REALLY CLEAR TO ME. IT IS A GOAL
9	THAT'S INDEPENDENT OF WHAT WE'RE TRYING TO
10	ACCOMPLISH WITH DISCOVERY STAGE AWARDS. AND IT
11	JUST I MEAN IT SEEMS LIKE THAT WE NEED TO MORE
12	DEVELOP THIS PROGRAM SO THAT WE CAN SPECIFY CERTAIN
13	OUTCOMES THAT WE WANT TO GET, AND I JUST DON'T THINK
14	PERSONALLY THAT THAT'S A GOOD USE OF EFFORT FOR WHAT
15	WE'RE TRYING TO ACCOMPLISH.
16	DR. STEWARD: I DON'T DISAGREE, JEFF. I
17	WAS TRYING TO FIND A MORE CLEARLY DEFINED PURPOSE.
18	THAT'S ALL. I AGREE WITH YOU. THIS ISN'T CLEARLY
19	RELATED TO THE OUTCOME THAT WE'RE SEEKING HERE. SO
20	I'M NOT AS YOU SAY, WHIPPED CREAM IS A GOOD
21	CHARACTERIZATION OF IT.
22	CHAIRMAN THOMAS: TO ME I'M GOING TO ECHO,
23	I THINK, WHAT JEFF AND MICHAEL ARE SAYING. THIS IS
24	NOT AS FAR AFIELD AS THE PREVIOUS ALLOCATIONS IN THE
25	CREATIVITY AWARDS TO THE CREATIVITY COMPONENT OF

1	THOSE AWARDS WHICH HAD NOTHING WHATSOEVER TO DO WITH
2	THE RESEARCH, BUT THIS IS NOT DIRECTLY RELEVANT TO
3	THE PROJECT AT HAND. SO I AGREE THAT I THINK THIS
4	IS SOMETHING THAT'S BETTER SPENT ON MORE GRANTS.
5	CHAIRMAN SHEEHY: ARE THERE ANY OTHER
6	COMMENTS OR DISCUSSION? I THINK WE CAN PROBABLY
7	DEAL WITH THIS. THE FUNDING ASPECTS WHICH WE HAVE A
8	SEPARATE THANK YOU TO DR. FRIEDMAN A SEPARATE
9	DISCUSSION ON. ANY OTHER COMMENTS?
10	DR. STEWARD: YEAH. I DO WANT TO ALERT, I
11	GUESS, EVERYONE TO I'M NOT YET CONVINCED ABOUT
12	THE INCENTIVE AND THE DETAILS THEREOF. SO I'M JUST
13	GOING TO PUT THAT OUT THERE, AND I'D LIKE VERY MUCH
14	TO HEAR SOME FURTHER DISCUSSION ON THAT, ESPECIALLY
15	FROM THE INSTITUTIONAL FOLKS.
16	DR. SHEPARD: OKAY. SO SPEAKING OF THE
17	INCENTIVES, MY NEXT SLIDE IS TO DESCRIBE HOW THAT
18	INCENTIVE PROGRAM WOULD WORK. SO BASICALLY, AS I
19	MENTIONED, THE GOAL OF ONE OF OUR QUEST AWARDS IS TO
20	ACHIEVE A CANDIDATE THAT CAN PROGRESS INTO
21	TRANSLATION STAGE RESEARCH. IDEALLY OR AS ONE
22	POSSIBLE WAY TO DO THAT, A QUEST AWARDEE COULD
23	COMPETE AND SUCCESSFULLY ACHIEVE A CIRM
24	TRANSLATIONAL PROGRAM AWARD TO CONTINUE THAT
25	FUNDING. ANOTHER POSSIBILITY IS THEY COULD WORK
	a r

1	WITH A COLLABORATOR AND OBTAIN FUNDING THROUGH
2	ANOTHER AGENCY OR WORK WITH A COMPANY TO
3	COLLABORATE. IT MAY EVEN BE POSSIBLE THAT THIS TEAM
4	THAT PERFORMED THE DISCOVERY AWARD DOESN'T HAVE THE
5	RIGHT EXPERTISE TO TAKE IT INTO TRANSLATION IN WHICH
6	CASE THEY MAY WANT TO PASS THE BATON OR HAND THIS
7	PROGRAM OFF TO A TEAM THAT HAS THOSE QUALIFICATIONS.
8	SO THIS IDEA OF A PROGRESSION EVENT,
9	FINDING A WAY TO EITHER TAKE THE PROGRAM FURTHER OR
10	HAND IT OFF TO SOMEBODY WHO CAN AND ACHIEVE THE
11	FUNDING TO ENABLE THAT IS WHAT WE CALL PROGRESSION
12	EVENT. AND WE WANT TO INCENTIVIZE PEOPLE TO USE IT.
13	SO WHAT WE ARE THINKING OF DOING IN THIS
14	PROGRAM IS OFFERING A REWARD FOR ACHIEVING A
15	PROGRESSION EVENT WITHIN ONE YEAR OF THE QUEST AWARD
16	END DATE. AND THAT WOULD BE, QUITE SIMPLY, AN
17	INCEPTION-LIKE GRANT OF A \$150,000 DIRECT PROJECT
18	COSTS TO CONDUCT EXPLORATORY RESEARCH OF THEIR
19	CHOOSING SO LONG AS IT'S ALIGNED WITH CIRM'S
20	MISSION.
21	NOW, TO MAKE THIS WORK EFFECTIVELY, WHAT
22	WE WOULD DO IS A GRANTEE WHO SUCCESSFULLY ACHIEVED A
23	PROGRESSION EVENT, BELIEVED THEY HAD DONE SO, WOULD
24	SUBMIT EVIDENCE THAT THEY HAVE ACHIEVED THIS
25	PROGRESSION EVENT TO CIRM WHO WOULD LOOK AT THAT TO
	26

1	MAKE SURE THAT THE CRITERIA FOR THAT HAD ACTUALLY
2	BEEN MET. WE'D LOOK AT THE PROPOSAL FOR WHAT THEY
3	WANT TO DO WITH THEIR INCENTIVE GRANT, MAKE SURE
4	IT'S ALIGNED WITH CIRM'S MISSION, AND THEN WE WOULD
5	NEED DELEGATION OF THE BOARD'S AUTHORITY TO MAKE
6	THAT AWARD AT THAT TIME.
7	SO THAT, SIMPLY STATED, IS HOW THE
8	INCENTIVE GRANT PROGRAM WOULD WORK. AND I'D BE
9	HAPPY TO TAKE SOME QUESTIONS OR CLARIFY THAT BECAUSE
10	THIS IS A NEW CONCEPT FOR CIRM, AND I'M SURE THAT
11	THERE ARE PROBABLY SOME QUESTIONS ABOUT HOW THIS
12	WOULD WORK.
13	DR. OLSON: IF I COULD JUST MAKE ONE
L 4	COMMENT. AN IMPORTANT THING TO US, AND I THINK WHAT
15	MANY OF YOU HAVE HEARD RANDY SAY BEFORE, IS WE
16	REALLY WANT TO ENCOURAGE PEOPLE WHO HAVE ACTUALLY
L 7	BEEN SUCCESSFUL AT GETTING A CANDIDATE TO MOVE THAT
18	FORWARD IRRESPECTIVE AND TO MOVE IT FORWARD
19	TIMELY. SO THERE'S AN ELEMENT OF TIME HERE, WHICH
20	IS WHY YOU NOTICE WE HAVE A YEAR LIMIT ON THIS. WE
21	REALLY WANT PEOPLE TO MOVE THINGS FORWARD AS QUICKLY
22	AS POSSIBLE TO THE NEXT STAGE OF RESEARCH. AND SO
23	THIS IS REALLY TO INCENT PEOPLE TO DO THAT. AND WE
24	HOPE, WE HOPE THAT WE CAN BETTER OUR 30-PERCENT RATE
25	OR SO. I MEAN THAT WOULD BE REALLY GOOD IF WE

1	COULD.
2	SO THAT'S THE GOAL IS THE TIMELINESS AND
3	THE ACCELERATION CONCEPT. IT'S MOVE SUCCESSFUL
4	RESEARCH FORWARD IRRESPECTIVE OF WHETHER YOU'RE
5	MOVING FORWARD WITH IT OR NOT.
6	CHAIRMAN SHEEHY: SO, DR. STEWARD, I THINK
7	YOU HAD SOME QUESTIONS ABOUT THIS AND FOR OTHER
8	MEMBERS TOO.
9	DR. STEWARD: MY, I GUESS, POINT IS
10	STILL SOME CONCERN ISN'T THE RIGHT WORD. I JUST
11	HAVEN'T COME TO A CONCLUSION ON THIS MYSELF. THE
12	ISSUE IS GIVING MONEY FOR SOMETHING THAT HASN'T
13	UNDERGONE PEER REVIEW. AND THAT'S SORT OF WHAT THIS
14	REWARD ACTUALLY ENDS UP BEING. SO YOU GET YOUR
15	GRANT, YOU DO THE WORK THAT WAS PEER REVIEWED, YOU
16	GET YOUR PROGRESSION EVENT, AND THEN YOU GET
17	\$150,000 TO KIND OF DO WHATEVER. I'M JUST STILL NOT
18	COMPLETELY COMFORTABLE WITH THAT BOTH FROM THE POINT
19	OF VIEW OF SORT OF THE WAY WE OPERATE AND FROM THE
20	POINT OF VIEW OF THE WAY THIS WOULD POTENTIALLY SET
21	APART CIRM GRANTEES FROM OTHERS IN THE INSTITUTION.
22	SO THIS IS WHY I WANTED TO HEAR SOME
23	COMMENTS FROM OTHERS, AND I JUST APPRECIATE HEARING
24	OTHER THOUGHTS. THANK YOU.
25	DR. MILLS: OS, I JUST WANT TO TAKE

1	EXCEPTION TO THE DO WHATEVER COMMENT. TO MAKE IT
2	OPERATIONALLY EFFICIENT, WE WOULDN'T MAKE THEM GO
3	BACK THROUGH THE EXTERNAL REVIEW PROCESS, BUT WE
4	WOULD MAKE THEM GO THROUGH AN INTERNAL REVIEW
5	PROCESS, WHICH WOULD INCLUDE, ONE, VALIDATING WHAT
6	THEY'VE ACTUALLY DONE, THE PROGRESSION EVENT, BUT
7	THE OTHER THING WOULD BE TO MAKE SURE THAT THEIR
8	PROGRAM WAS SOMETHING MEANINGFUL TO CIRM. AND THEN
9	WE WOULD DO THAT INTERNALLY. IT'S NOT AND I
10	GUESS IT'S NOT THAT DIFFERENT AND ACTUALLY IT'S
11	PROBABLY EVEN LESS MONEY THAT USED TO BE AVAILABLE
12	UNDER DIFFERENT AUTHORITIES TO THE PRESIDENT THROUGH
13	OTHER KINDS OF DISCRETION AWARDS THAT I THINK WE'VE
14	GOTTEN AWAY WITH. SO IT'S A NEW CONCEPT BECAUSE
15	WE'RE REQUIRING THAT THERE ACTUALLY BE OBJECTIVE
16	PRODUCTIVITY IN ORDER FOR THERE TO BE THIS AWARD
17	MADE. BUT THE OTHER THINGS I DON'T BELIEVE ARE NEW.
18	DR. STEWARD: RANDY, LET ME APOLOGIZE. I
19	SAID THAT IN SORT OF A FLIPPANT WAY TO GET THROUGH
20	THE COMMENT QUICKLY. AND I TOTALLY UNDERSTAND THAT
21	THERE WOULD BE A LOOK AT THIS BY CIRM, A REVIEW OF
22	THIS BY CIRM. WHAT I REALLY MEANT TO SAY THAT THIS
23	WOULD BE WITHOUT SORT OF THE STANDARD OF PEER REVIEW
24	THAT CONSTITUTES KIND OF THE BASIS OF EVERY OTHER
25	AWARD THAT WE GIVE OUT.

1	SO, AGAIN, I JUST I'M NOT COMFORTABLE
2	WITH IT YET. I MAY BE BY THE END OF THIS
3	CONVERSATION, SO I JUST WANTED TO HEAR OTHER
4	COMMENTS ON IT. THANK YOU.
5	CHAIRMAN SHEEHY: SENATOR TORRES.
6	MR. TORRES: YES. I DO THINK THAT THE
7	DEFINITION I MEAN THESE TERMS ALL SOUND SO
8	MEDIEVAL, THE QUEST AWARD, THE INCENTIVE AWARD, BUT
9	I DON'T SEE A DEFINITION OF THE CRITERIA OTHER THAN
10	AWARDEE MUST SUBMIT EVIDENCE TO CIRM INDICATING
11	ADDITIONAL MONEY HAS BEEN ACQUIRED. THE DEFINITION
12	OF A PROGRESSION EVENT, I SEE IT IN THE TABLE, AND I
13	MUST SAY YOU'VE DONE AN EXCELLENT, KELLY, BUT I SEE
14	IT IN THE TABLE FROM DISCOVERY TO TRANSLATION, BUT
15	WHAT IS THE CRITERIA TO DETERMINE WHETHER A
16	PROGRESSION EVENT HAS OCCURRED?
17	DR. SHEPARD: SO THIS IS DESCRIBED IN A
18	LITTLE BIT MORE DETAIL ON THAT CONCEPT, BUT THE IDEA
19	IS SO WHEN SOMEBODY COMPLETES THEIR QUEST AWARD,
20	WHICH IS A TWO-YEAR PERIOD OF TIME, THEY SHOULD
21	HAVE, IF THEY WERE SUCCESSFUL AND THE SCIENCE WORKS
22	OUT, THEY SHOULD HAVE A CANDIDATE THAT IS READY FOR
23	TRANSLATION. THE GRANT ITSELF TO DEVELOP THE
24	CANDIDATE IS TWO YEARS. IF THEY'RE COMPLETELY
25	SUCCESSFUL, AT THAT POINT THEY WILL HAVE A CANDIDATE
	30

1	THAT'S READY FOR TRANSLATION. AT THAT POINT THE
2	CLOCK STARTS, AND THEN THEY HAVE A YEAR TO FIND A
3	WAY TO MOVE THAT ON EITHER BY GETTING A
4	TRANSLATIONAL GRANT FROM CIRM TO CONTINUE THAT
5	PROJECT OR BY FINDING A PARTNER TO TAKE THAT ON OR A
6	COLLABORATOR OR GETTING AN NIH GRANT, SOME OTHER
7	WAY. THEY JUST HAVE TO PROVIDE EVIDENCE TO CIRM
8	THAT, LOOK, HERE'S A PLAN TO MOVE FORWARD, HERE'S
9	THE FUNDING TO MOVE IT FORWARD, AND WE'RE EITHER
10	GOING TO DO IT OURSELVES OR WE'VE IDENTIFIED THIS
11	TEAM TO HELP US MOVE FORWARD.
12	AND WITH THAT EVIDENCE IN HAND, WE SAY,
13	OKAY, YOU'VE MET THE CRITERIA FOR PROGRESSION EVENT,
14	SO YOU ARE ELIGIBLE TO RECEIVE THE INCENTIVE GRANT.
15	BUT FIRST YOU HAVE TO SHOW US WHAT YOU WANT TO USE
16	THAT INCENTIVE GRANT TO DO AND THE BUDGET FOR IT,
17	AND WE NEED TO MAKE SURE IT'S ALIGNED WITH CIRM'S
18	MISSION.
19	MR. TORRES: SO WHERE DOES A GRANTEE GO TO
20	DETERMINE THE CRITERIA FOR THE PROGRESSION EVENT?
21	DR. OLSON: IT REALLY IS DO YOU HAVE
22	FUNDING TO TAKE THE CANDIDATE FORWARD.
23	MR. TORRES: AND THAT DEFINES PROGRESSION?
24	DR. OLSON: THAT DEFINES PROGRESSION.
25	MR. TORRES: PROGRESSION IS DO YOU HAVE
	21
	31

1	THE MONEY TO MOVE FORWARD?
2	DR. OLSON: DO YOU HAVE THE MONEY AND DID
3	YOU GET IT WITHIN ONE YEAR OF THE END OF YOUR QUEST
4	AWARD?
5	MR. TORRES: PROGRESSION DOES NOT DEFINE
6	THE SUCCESS OF A PARTICULAR TREATMENT OR TECHNOLOGY.
7	IT DEFINES WHETHER YOU HAVE MORE MONEY?
8	DR. OLSON: NO. YOU HAVE TO HAVE HAD A
9	CANDIDATE. AT THE END OF THE QUEST AWARD, YOU HAVE
10	A CANDIDATE THAT'S READY TO MOVE FORWARD. THE
11	PROGRESSION IS IS THIS CANDIDATE, DO YOU HAVE
12	FUNDING TO TAKE THAT CANDIDATE, SAY, INTO
13	PRECLINICAL DEVELOPMENT, OR DO YOU HAVE MONEY TO
14	TAKE THAT DIAGNOSTIC TEST INTO THE NEXT STAGE OF
15	DEVELOPMENT IF YOU'VE GOT A PARTNER? AND IT'S THE
16	APPROPRIATE AND IT'S, YES, IT'S MONEY AND THE
17	NEXT STAGE.
18	DR. SHEPARD: IT'S MOVEMENT TOWARDS. IT'S
19	NOT SITTING IN LIMBO IN DISCOVERY ZONE. IT'S MOVING
20	TOWARDS A PATIENT. THERE'S A CERTAIN SERIES OF
21	EVENTS THAT HAVE TO HAPPEN IN ORDER FOR A DISCOVERY
22	TO GET TO A PATIENT. AND IT CAN EITHER STAY THERE
23	IN LIMBO OR IT CAN MOVE, BUT IT TAKES MONEY TO MOVE
24	IT. IT NEEDS TO MOVE TO TREATMENT THOUGH.
25	DR. FRIEDMAN: BUT IF YOU ALREADY HAVE THE
	32

1	MONEY, I GUESS I DON'T UNDERSTAND THE ADDITIONAL
2	VALUE. I SEE CONSIDERABLE VALUE FOR FINDING A
3	PARTNER, AND THAT PART OF YOUR PROPOSAL APPEALS TO
4	ME GREATLY, ESPECIALLY IF WE WERE TO WORK OUT SOME
5	WAY IN WHICH OUR CIRM SCIENTIFIC STAFF IS BOTH
6	KNOWLEDGEABLE AND HELPFUL AND COULD REALLY
7	FACILITATE THE MATCHMAKING. THAT STRIKES ME AS A
8	REALLY CLEVER IDEA, AND I'M SURE THAT'S WHAT YOU ALL
9	WERE THINKING OF HOW TO MAKE THOSE CONNECTIONS.
10	THAT DOES ADD VALUE. I JUST DON'T UNDERSTAND. IF
11	YOU'VE ALREADY GOT AN NIH AWARD, WHY DO YOU NEED THE
12	\$150,000? I MEAN EVERYBODY NEEDS MORE MONEY. I GET
13	THAT. I REALLY DO. NONE OF THESE AWARDS ARE
14	SUFFICIENT.
15	DR. MILLS: WHERE THIS COMES FROM REALLY
16	IS AND I'LL TELL YOU GUYS, WE HAVE JUST BRUTALLY
17	HONEST CONVERSATIONS WITH PEOPLE ABOUT IT WHERE THEY
18	DON'T WANT THEIR PROGRAM TO MOVE DOWNSTREAM. AND
19	THE REASON THEY DON'T WANT THEIR PROGRAM TO MOVE
20	DOWNSTREAM IS THEY DON'T DO DOWNSTREAM WORK. THEY
21	DO THE WORK IN THAT PARTICULAR, LET'S CALL IT, TRAIN
22	STATION. THEY DON'T WANT TO GO TO THE NEXT TRAIN
23	STATION WITH THIS. AND SO THE PROBLEM THAT IS
24	THEY'RE INCENTIVIZED TO MAKE THEIR PROGRAM TAKE AS
25	LONG AS IT POSSIBLY CAN AND THEN COME UP WITH NEW

1	QUESTIONS AND IDEAS TO ASK ABOUT IT SO THEY CAN STAY
2	IN EARLY STAGE RESEARCH. AND THEY'RE
3	DISINCENTIVIZED RIGHT NOW TO HAVE THAT RESEARCH GO
4	DOWNSTREAM. SO THAT'S
5	DR. FRIEDMAN: RANDY, I GET THAT. WHY
6	DON'T YOU THEN SAY THAT THEY NOT ONLY HAVE RESOURCES
7	TO GO FORWARD, BUT THEY MUST HAVE A PARTNER TO GO
8	FORWARD?
9	DR. MILLS: IT'S PART OF WHAT WILL BE IN
10	THE APPLICATION PROCESS. SO WE'RE DOING TWO THINGS
11	THERE. ONE IS THEY HAVE TO DESCRIBE IF THIS WORKS
12	OUT, WHAT ARE THEY GOING TO DO WITH IT. IF IT'S
13	SUCCESSFUL, HOW IS IT GOING TO GO TO THE NEXT TRAIN
14	STATION? AND TWO, WE'RE INTRODUCING THIS CONCEPT
15	WE CALL IT THE EXCHANGE. IT'S KIND OF THE MATCH.COM
16	OF THIS RESEARCH WHERE WE HELP THEM IDENTIFY
17	DIFFERENT PARTNERS.
18	BUT I THINK RIGHT NOW WHAT WE'VE HEARD
19	FAIRLY OVERWHELMINGLY FROM THESE GUYS IS THAT ABSENT
20	US DOING SOMETHING HERE, THEY'RE ALMOST
21	DISINCENTIVIZED FOR THEIR CARGO TO GO DOWNSTREAM
22	WHERE WE WANT IT TO GO RIGHT NOW.
23	DR. OLSON: AND EVEN FOR THOSE, SAY,
24	PHYSICIAN SCIENTISTS WHO ARE ACTUALLY DOING
25	CANDIDATE DISCOVERY, THERE SEEMS TO BE A STRONG

1	PENCHANT THAT YOU CAN ALWAYS MAKE SOMETHING BETTER.
2	AND THAT DOESN'T MOVE THINGS FORWARD QUICKLY EITHER.
3	SO EVEN THE PHYSICIAN SCIENTISTS WHO MIGHT WANT TO
4	CARRY SOMETHING TO THE NEXT STAGE, SOMETIMES A
5	LITTLE PUSH, IS IT GOOD ENOUGH IF YOU COULD REALLY
6	BENEFIT PATIENTS BY MOVING THIS FORWARD? SO I THINK
7	JUST IT'S THE PEOPLE WHO DON'T WANT TO MOVE, IT'S
8	THE PEOPLE WHO HOW MUCH IS GOOD ENOUGH, AND IT'S
9	ALSO THE EXTERNAL YOU KNOW, GETTING EXTERNAL
10	FUNDING IS A VALIDATION IN MANY CASES THAT WHAT
11	YOU'RE DOING IS NOT JUST IMPORTANT TO YOU. IT'S
12	IMPORTANT TO THE FIELD, YOUR PEERS THINK IT'S
13	IMPORTANT IF THE END GAME IS IS IT
14	COMMERCIALLY IS THIS AN UNMET NEED? IT'S THAT
15	тоо.
16	SO I THINK JUST SUCCESS IN ACHIEVING
17	FUNDING ARGUES AS A VALIDATION, AND NOT EVERYTHING
18	THAT IS SUCCESSFUL AT GETTING A CANDIDATE WILL
19	NECESSARILY MOVE.
20	MR. TORRES: AH, THAT'S DISTURBING.
21	DR. OLSON: IT'S JUST TRUE.
22	MR. TORRES: I KNOW, BUT IT'S DISTURBING
23	THAT A PATIENT HAS TO BE AT THE MERCY OF PEOPLE WHO
24	DON'T WANT TO MOVE FORWARD. AND I THINK THIS IS A
25	GREAT IF WE PROVIDE A MECHANISM BY HELPING THEM
	35
	ı U.

1	MOVE FORWARD, THAT'S ULTIMATELY IN THE FAVOR OF THE
2	PATIENT.
3	DR. OLSON: IT IS.
4	CHAIRMAN SHEEHY: BECAUSE I WANT TO GIVE
5	OTHER FOLKS AN OPPORTUNITY TO WEIGH IN ON THIS, DO
6	WE HAVE BECAUSE I THINK OS HAD MADE A CALL TOO.
7	I THINK DR. FRIEDMAN HAS WEIGHED IN, BUT WHAT DOES
8	THIS MAKE SENSE BASED ON HOW YOUR INSTITUTIONS WORK
9	AND YOUR EXPERIENCE THAT THIS WAS SOMETHING THAT
10	WOULD BE SUCCESSFUL IN ACHIEVING THE AIMS THAT WE'RE
11	TRYING TO ACHIEVE HERE? ANY THOUGHTS ON THAT?
12	DR. LUBIN: SO IT WOULD SEEM TO ME THAT
13	WHEN YOU FIRST GAVE THE AWARD, THE PLAN WAS TO
14	DEVELOP SOMETHING THAT WOULD TRANSLATE INTO SOME
15	THERAPY. IS THAT NOT TRUE?
16	DR. SHEPARD: THAT'S TRUE, YES.
17	DR. MILLS: THAT WILL BE TRUE NOW.
18	DR. LUBIN: DURING THOSE TWO YEARS THAT
19	YOU'RE SUPPORTING PEOPLE, ANYBODY THAT HAS SOMETHING
20	THAT THEY THINK IS GOING TO GO INTO A CLINICAL THING
21	WILL THINK ABOUT WRITING AN NIH GRANT OR THINK ABOUT
22	A PARTNER TO SUSTAIN THEIR FUNDING AFTER THE END OF
23	THE TWO YEARS. I MEAN THAT'S WHAT THIS LIFE IS LIKE
24	RIGHT NOW. SO I'M A LITTLE UNCLEAR WHY MORE MONEY
25	IS NEEDED TO DO THAT UNLESS THERE WAS A CONVINCING
	36

1	CASE THAT YOU'VE TRIED THOSE THINGS, BUT YOU NEED TO
2	GENERATE SOME MORE DATA BEFORE YOU'RE GOING TO BE
3	ACCEPTED FOR EITHER AN NIH GRANT OR AN INDUSTRY
4	PARTNER.
5	DR. MILLS: IT'S MORE ALONG THE LINES OF
6	FOR THE PEOPLE THAT, LET'S SAY, DO EARLY STAGE
7	RESEARCH THAT UNDERSTAND MECHANISMS OR WHAT HAVE
8	YOU, AND THAT'S WHAT THEY WANT TO DO. THEY DON'T
9	KNOW HOW TO DO TRANSLATIONAL WORK. THEY DON'T WANT
10	TO LEARN HOW TO DO TRANSLATIONAL WORK. THEY DO
11	EARLY STAGE WORK. BUT THEY'RE VERY GOOD AT IT, AND
12	IT'S A VERY NECESSARY THING. RIGHT NOW WE HAVE
13	NO THEY HAVE NO INCENTIVE FOR THEM TO TRY TO FIND
14	A HOME FOR THEIR PROGRAM ONCE IT EXCEEDS THEIR
15	ABILITY AND INTEREST LEVEL TO CARRY IT FORWARD. AND
16	THAT'S WHAT THIS IS DESIGNED.
17	I MEAN I HEAR QUESTIONS ABOUT PEOPLE ARE
18	MAYBE NOT SURE IF IT WILL WORK. I WOULD TURN IT
19	AROUND THE OTHER WAY. ARE YOU THAT SURE IT WON'T
20	WORK? BECAUSE WHEN WE DON'T DO SOMETHING, WE HAVE A
21	5-PERCENT SPONTANEOUS PROGRESSION RATE. AND I GET
22	IT. IT'S NEW AND IT'S DIFFERENT, BUT I THINK NEW
23	AND DIFFERENT WE MIGHT NEED TO CONSIDER BECAUSE OLD
24	DIDN'T WORK.
25	DR. STEWARD: RANDY, THIS IS OS. AND I
	37

1	GUESS ONE OF THE THINGS THAT IS STILL JUST SORT OF
2	THE NAGGING AT ME IS THE IDEA THAT THIS IS SOME KIND
3	OF REWARD THAT IN A SENSE PUSHES OR ENABLES PEOPLE
4	TO TURN AWAY FROM TRANSLATION. I'D BE A LOT MORE
5	ENTHUSIASTIC AND COMFORTABLE WITH THIS IF IT WAS
6	FRAMED IN A WAY THAT, YES, THERE'S AN INCENTIVE TO
7	ACTUALLY DO ADDITIONAL STUDIES TO EXPAND THE REACH
8	OF WHATEVER YOU HAVE TO ACTUALLY IMPROVE THE ABILITY
9	OF THE TREATMENT OR THERAPY TO ACTUALLY TARGET A
10	DIFFERENT POPULATION. SOMETHING ALONG THOSE LINES.
11	I'M JUST STILL REALLY UNCOMFORTABLE WITH THE IDEA OF
12	YOU DO THE WORK TO GET YOU TOWARD A GOAL AND THEN
13	YOU GET A REWARD TO GO BACK AND KIND OF START ALL
14	OVER AGAIN. ANYWAY, I'M NOT SAYING IT VERY WELL,
15	BUT I'M JUST STILL NOT CONVINCED.
16	DR. MILLS: I'M A BIG OPPONENT OF PROGRAMS
17	THAT ASK FISH TO LEARN HOW TO FLY. IF A FISH JUST
18	WANTS TO SWIM AND THEY'RE VERY GOOD AT THAT, I THINK
19	THE IDEA THAT WE'RE GOING TO TRY TO TURN THEM INTO
20	BIRDS BECAUSE THE NEXT STAGE REQUIRES BEING A BIRD,
21	IT DOESN'T MAKE SENSE. IT DOESN'T FLY.
22	CHAIRMAN SHEEHY: CAN I ASK A QUESTION
23	JUST FOR CLARIFICATION? SO A PROGRESSION EVENT
24	COULD BE SOMEBODY TAKES YOUR PROJECT ON WITH
25	ADDITIONAL FUNDING, BUT IT COULD ALSO BE YOU

1	YOURSELF, YOU'RE TAKING IT ON. THIS MAY BE YOUR
2	FIRST TIME THAT YOU PUT YOUR BOAT INTO THE
3	TRANSLATION RIVER, AND THEN MAYBE THIS MIGHT
4	MOTIVATE SOME FOLKS TO TAKE THAT LEAP, RIGHT. SO IT
5	COULD BE EITHER WAY.
6	DR. MILLS: ABSOLUTELY.
7	CHAIRMAN SHEEHY: SO WE'RE NOT RESTRICTING
8	IT JUST TO FOLKS WHO ARE PASSING THE BATON.
9	DR. OLSON: RIGHT. SO IT WOULD BE UP TO
10	THE GRANTS WORKING GROUP TO DETERMINE IF IT, IN
11	FACT, WAS THE SAME PI WHO WAS MOVING IT FORWARD,
12	HAVE THAT PI PUT TOGETHER A TEAM THAT WAS CAPABLE OF
13	DOING THAT. AND THAT'S AN IMPORTANT CRITERIA, AS
14	YOU ALL WELL KNOW WHO SIT ON THE GRANTS WORKING
15	GROUP. CAN THEY DO IT? SO IN ORDER TO GET THE
16	INCENTIVE AWARD, THEY STILL HAVE TO GET FUNDING.
17	CHAIRMAN SHEEHY: I WAS A LITTLE CONFUSED
18	BY THAT, BUT I THINK IT'S PROBABLY HELPFUL IF WE CAN
19	JUST ARE THERE ANY OTHER QUESTIONS ON THIS POINT
20	AND MAYBE WE CAN MOVE FORWARD? OKAY. DR. SHEPARD.
21	DR. SHEPARD: OKAY. FINALLY, I'VE COME TO
22	THE CHALLENGE AWARD SLIDE, PA 15-09. THIS IS THE
23	THIRD OF THE THREE DIFFERENT TYPES OF DISCOVERY
24	AWARD PROGRAMS.
25	THIS IS TO ADDRESS A VERY SPECIFIC PROBLEM
	39

1	THAT EITHER COMES UP OR IS A NEW DEVELOPMENT THAT
2	HADN'T BEEN ANTICIPATED. SO THE GOAL IS TO ADDRESS
3	WHAT WE CALL A HIGHLY SPECIFIC QUESTION THAT WOULD
4	BE ISSUED THROUGH A PERIODIC CHALLENGE QUESTION
5	ANNOUNCEMENT.
6	SO THE RESEARCH GOALS, LEVEL OF SUPPORT,
7	THE AWARD DURATION, AND ELIGIBLE ACTIVITIES WOULD BE
8	TAILORED TO WHATEVER THAT SPECIFIC QUESTION MIGHT
9	BE. IT WOULD BE APPROVED BY THE PRESIDENT OF CIRM
10	OR HIS DELEGATE.
11	NOW THE NEXT BULLET IS ABOUT THE
12	ENRICHMENT FUNDS WHICH WERE A TOPIC OF DISCUSSION
13	EARLIER AND WE'RE GOING TO COME BACK TO, SO WE WON'T
14	GO OVER THAT.
15	NOW, UNLIKE THE OTHER TWO TYPES OF
16	PROGRAMS I DESCRIBED, WE EXPECT THE APPLICATION
17	VOLUME TO BE VERY LOW FOR THESE BECAUSE OF THE
18	SPECIFICITY OF THE QUESTION TARGETED. MAYBE FIVE TO
19	TEN.
20	NOW, THE NEXT SLIDE I'M GOING TO TALK
21	ABOUT IS THE STREAMLINED REVIEW PROCESS THAT WE'RE
22	PROPOSING FOR THE ROUNDS THAT HAVE HIGH VOLUME OF
23	APPLICATIONS, PARTICULARLY QUEST AND INCEPTION.
24	SO WHAT WE'RE PROPOSING IS ACTUALLY
25	CHAIRMAN SHEEHY: I'M SORRY. COULD WE
	40

_	
1	JUST SEE IF THERE'S ANY QUESTIONS ON QUEST?
2	DR. SHEPARD: OH, SORRY. I'M SORRY.
3	DR. HIGGINS: ARE THERE ANY EXAMPLES OF
4	THE KIND OF CHALLENGE QUESTIONS?
5	DR. SHEPARD: WELL, EXAMPLE I'VE HEARD
6	RANDY GIVE ON A COUPLE OF OCCASIONS IS ONE OF OUR
7	PROGRAMS IN OUR DISEASE TEAM PORTFOLIO NEEDS A
8	POTENCY ASSAY, BUT THERE'S NOT REALLY ANYBODY ON
9	THAT PARTICULAR TEAM WITH THE BASIC RESEARCH SKILLS
10	TO DEVELOP IT. SO WE COULD PUT OUT A CALL SAYING
11	THAT WE NEED A POTENCY ASSAY FOR THIS SPECIFIC CELL
12	TYPE, DEFINE THE CRITERIA OF WHAT WE NEED, AND
13	SOLICIT SOME APPLICATIONS FROM SOME INVESTIGATORS
14	WHO THINK THEY HAVE THE ABILITY IN THEIR LAB TO
15	ADDRESS THAT QUESTION.
16	CHAIRMAN SHEEHY: DID THAT ANSWER YOUR
17	QUESTION?
18	DR. SHEPARD: OKAY. SO THE NEXT THING I
19	WANT TO GO OVER VERY BRIEFLY IS WHAT IS COVERED IN
20	THE APPENDIX THAT WAS INCLUDED IN THE AGENDA. THIS
21	IS OUR PROPOSAL FOR A STREAMLINED WAY TO HELP US GET
22	THROUGH APPLICATION CYCLES WHERE THERE'S A VERY
23	LARGE NUMBER OF APPLICATIONS EFFICIENTLY AND
24	EFFECTIVELY. SO WHAT WE'RE PROPOSING IS A TWO-STAGE
25	REVIEW PROCESS WHICH WILL BE CONDUCTED BY THE GRANTS
	41

1	WORKING GROUP; THAT IS, THE 15 SCIENTIFIC MEMBERS AS
2	WELL AS THE 7 PATIENT ADVOCATE MEMBERS OF THE GRANTS
3	WORKING GROUP.
4	IN THIS FIRST STAGE OF THE PROCESS, THEY
5	WOULD SCREEN, CONDUCT A PREREVIEW OF ALL OF THE
6	SUBMITTED APPLICATIONS AND SELECT A SUBSET OF THEM
7	TO MOVE FORWARD TO THE SECOND STAGE OF REVIEW.
8	THE SECOND STAGE WOULD BE THE STANDARD
9	IN-PERSON GRANTS WORKING GROUP REVIEW MEETING WHERE
10	THE APPLICATIONS ARE ASSIGNED TO REVIEWERS, SCORED,
11	AND FUNDING RECOMMENDATIONS ARE THEN BROUGHT TO THE
12	BOARD.
13	WE BELIEVE THAT THIS APPLICATION OFFERS
14	SEVERAL PROCESS OFFERS SEVERAL IMPROVEMENTS.
15	IT'S A SINGLE-STEP APPLICATION PROCESS FOR THE
16	APPLICANT, WHICH MEANS NO PRELIMINARY APPLICATIONS,
17	WHICH IS HOW WE HANDLED HIGH VOLUMES IN THE PAST,
18	WHICH CUTS SOME OF THE TIME OUT OF THE TIMELINE IN
19	PROCESSING AND REVIEWING THE AWARD. WE THINK THIS
20	PROCESS IS SCALABLE IN RESPONSE TO APPLICATION
21	VOLUME; IN OTHER WORDS, WOULD WORK WELL FOR 500
22	APPLICATIONS VERSUS 300 VERSUS 100. AND WE BELIEVE
23	IT CAN FACILITATE SELECTION OF PROPOSALS WITH THE
24	HIGHEST POTENTIAL FOR IMPACT FROM A BROAD APPLICANT
25	POOL.

1	CHAIRMAN THOMAS: WHAT CRITERIA DO YOU
2	ASSIGN TO THE GWG IN THE PREREVIEW PROCESS?
3	DR. SHEPARD: WELL, THERE ARE REVIEW
4	CRITERIA THAT ARE SPECIFIED IN THE PROGRAM
5	ANNOUNCEMENT FOR THE OVERALL PROGRAM. SO WHAT THEY
6	WILL BE LOOKING AT IS STATEMENT OF IMPACT AND HOW
7	THIS CAN POTENTIALLY HELP PATIENTS AND DEFINE THE
8	GOALS TO BE REALIZED AND A BRIEF SUMMARY OF WHAT THE
9	SCIENTIFIC GOALS ARE AND THE RATIONALE. AND IT WILL
10	BE UP TO THE REVIEWERS, GRANTS WORKING GROUP,
11	(INAUDIBLE) TO USE THEIR JUDGMENT BASED ON THE
12	(INAUDIBLE) WHICH WILL HAVE THE MOST POTENTIAL TO
13	IMPACT PATIENTS (INAUDIBLE).
14	CHAIRMAN THOMAS: THANK YOU.
15	CHAIRMAN SHEEHY: SO IS THERE ANOTHER
16	SLIDE FOR THIS?
17	DR. SHEPARD: NO. THE MAJOR DETAILS ARE
18	IN THE APPENDIX; AND IF YOU HAVE ANY QUESTIONS, I'M
19	HAPPY TO ANSWER THEM.
20	CHAIRMAN SHEEHY: SO I WAS GOING TO ASK IF
21	ANYBODY HAD ANY QUESTIONS ON THIS PROCESS? THE
22	APPENDIX REALLY LAYS IT OUT VERY NICELY.
23	AND THE ONLY POINT I WOULD LIKE TO MAKE,
24	WHICH MAY NOT BE IN THE SLIDE, IS THAT THE SCORING
25	SYSTEM WILL BE DIFFERENT. ARE WE GOING TO SEE A
	//3

1	SLIDE ON THAT? WE'RE GOING BACK TO THE ONE TO A
2	HUNDRED, AND THERE WON'T BE MAYBE SOMEBODY COULD
3	JUST VERY BRIEFLY TALK ABOUT THE SCORING SYSTEM.
4	DR. MILLS: THE SCORING GOES BACK TO ONE
5	TO A HUNDRED FOR THESE, AND THE REASON FOR THAT IS
6	WE ANTICIPATE THERE BEING MORE SUPPLY OF THESE
7	APPLICATIONS THAN WE WILL HAVE SLOTS. SO NOT ONLY
8	WILL WE HAVE TO GET A FUNDABLE SCORE, WE WILL THEN
9	NEED TO RANK ORDER THEM IN SOME WAY BECAUSE WE
10	BELIEVE WE MIGHT HAVE 400 AND NEED TO FUND THE TOP
11	20. SO WE'LL NEED SOME WAY OF RANKING THEM IS WHY
12	WE CAN'T USE THE ONE, TWO, THREE.
13	CHAIRMAN SHEEHY: SO IT WILL BE I THINK
14	BASICALLY WHAT WILL COME TO THE BOARD WILL RESEMBLE
15	WHAT HAS COME TO THE BOARD IN THE PAST, THREE TIERS.
16	DR. MILLS: YEAH. WHAT WE'RE HOPING IS WE
17	JUST GET EVERYTHING THAT'S EVEN PLAUSIBLY FUNDABLE
18	WOULD BE WELL IN TIER I. AND THEN OUT OF THAT, HERE
19	ARE THE TOP 20.
20	CHAIRMAN SHEEHY: OKAY.
21	DR. MILLS: SO WE WOULD END UP WITH A
22	LOT EVERYTHING WOULD BE TIER I THAT WOULD GET
23	FUNDED, AND ONLY A SUBSET OF THAT.
24	CHAIRMAN THOMAS: SO THERE WILL BE NO TIER
25	II PROGRAMMATIC DISCUSSION CONTEMPLATED IN THIS?
	4.4

1	DR. MILLS: YOU GUYS HAVE THE ABILITY TO
2	FUND WHATEVER YOU WANT, BUT OUR WE'LL HAVE TO SEE
3	WHAT WE GET FROM AN APPLICATION STANDPOINT, BUT WE
4	THINK THERE'S GOING TO BE MORE APPLICATIONS THAN
5	THERE WILL BE MINIMALLY FUNDABLE PROGRAMS. I COULD
6	BE WRONG. WE'LL HAVE TO SEE.
7	CHAIRMAN SHEEHY: JUST A PROCESS QUESTION.
8	I'M FINE WITH WHATEVER, BUT DO WE WANT TO LOOK AT
9	OUR TIERS AND MAYBE END UP WITH TWO TIERS AND MAYBE
10	SET THE SCORES HIGHER IF THAT'S YOUR GOAL IS TO NOT
11	TO FUND I JUST I'M JUST IMAGINING TRYING TO
12	HAVE THAT CONVERSATION AT THE BOARD. BUT I DON'T
13	KNOW. DO OTHER MEMBERS HAVE THOUGHTS ON THIS?
14	WE'LL JUST SEE HOW IT GOES.
15	DR. MILLS: AND THE OTHER THING TOO ABOUT
16	THIS, WHICH IS A LITTLE DIFFERENT THAN THE OLD ONE
17	TO A HUNDRED SYSTEM, IS BECAUSE THIS ISN'T A
18	ONE-TIME RFA, THIS ISN'T THE WHACK A MOLE THING
19	WHERE IT GOES AWAY AND YOU DON'T KNOW WHEN IT'S
20	COMING BACK, THESE ARE EVERY SIX MONTHS. SO THERE
21	IS NO NEED TO APPEAL EVEN FOR THIS. YOU JUST APPLY.
22	AND BY THE TIME YOU'RE DONE WITH THAT, YOU'RE UP FOR
23	REVIEW AGAIN AND THERE YOU ARE.
24	CHAIRMAN SHEEHY: AND, OF COURSE, THE
25	BOARD ALWAYS HAS THE ABILITY TO FUND
	45

1	DR. MILLS: TO DO WHATEVER THEY WANT.
2	CHAIRMAN SHEEHY: THEY COULD FUND THE
3	ENTIRETY OF TIER I, ETC. OKAY.
4	DR. SHEPARD: ANYTHING ELSE?
5	CHAIRMAN SHEEHY: I THINK SO FAR SO GOOD.
6	WHAT'S THE NEXT.
7	DR. SHEPARD: LET ME WRAP UP BY
8	SUMMARIZING WHAT THE REQUESTED BOARD DECISIONS ARE
9	TO IMPLEMENT THE CONCEPT AS DESCRIBED. WE WOULD ASK
10	FOR A FUNDING ALLOCATION OF \$52.5 MILLION FOR THE
11	DISCOVERY STAGE PROGRAMS FOR THEIR FIRST YEAR. 44
12	MILLION OF THIS IS FOR THE AWARDS BETWEEN THE THREE
13	PROGRAMS, INCEPTION, QUEST, AND CHALLENGE. 7.5
14	MILLION OF THAT WOULD BE RESERVE FUNDING FOR
15	INCENTIVE GRANTS FOR QUEST AWARDEES WHO DO ACHIEVE
16	PROGRESSION EVENTS. THIS IS ASSUMING A HUNDRED
17	PERCENT SUCCESS, WHICH IS EXTREMELY UNLIKELY, BUT WE
18	DO NEED TO HAVE SOME FUNDING SET ASIDE TO MAKE THAT
19	POSSIBLE7 IS FOR THE ENRICHMENT SUPPLEMENTS
20	WHICH WERE A TOPIC OF DEBATE, BUT THAT'S HOW THAT
21	BREAKS DOWN.
22	FOR THE PROCESS CHANGES THAT I SUGGESTED,
23	WE ALSO WOULD REQUEST DELEGATION OF BOARD AUTHORITY
24	TO THE PRESIDENT OR HIS DESIGNEE. ONE FOR THE
25	REVIEW PROCESS IN THAT FIRST STAGE WE DESCRIBED IN

46

1	THE APPENDIX TO EXAMINE APPLICATIONS NOT SELECTED
2	FOR THE SECOND STAGE OF GWG REVIEW, MAKE A FINAL
3	DETERMINATION WHETHER TO SUBMIT THOSE TO THE SECOND
4	STAGE, OR TO DENY FUNDING.
5	THE SECOND IS TO AWARD THE INCENTIVE
6	GRANTS UPON DETERMINATION THAT A PROGRESSION EVENT
7	HAS BEEN ACHIEVED AND THAT THE INCENTIVE GRANT
8	PROPOSAL AND BUDGET IS ALIGNED WITH CIRM'S MISSION.
9	AND THE THIRD IS TO ISSUE THE PERIODIC
10	CHALLENGE QUESTION ANNOUNCEMENTS THAT DEFINE THE
11	SPECIFIC TOPIC AND THE CORRESPONDING AWARD TERMS
12	UNDER THE CHALLENGE AWARDS PROGRAM ANNOUNCEMENT
13	15-09.
	CHAIRMAN SHEEHY: SO JUST A COUPLE OF
14	CHAIRMAN SHEERT. SO JUST A COUPLE OF
14 15	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY
15	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY
15 16	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE
15 16 17	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE NOT SELECTED BY THE WORKING GROUP IN THE FIRST STAGE
15 16 17 18	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE NOT SELECTED BY THE WORKING GROUP IN THE FIRST STAGE OF THE PROCESS, IN GENERAL PART OF THAT GOAL IS TO
15 16 17 18 19	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE NOT SELECTED BY THE WORKING GROUP IN THE FIRST STAGE OF THE PROCESS, IN GENERAL PART OF THAT GOAL IS TO MAKE SURE THAT YOU REVIEW A REASONABLE NUMBER OF
15 16 17 18 19	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE NOT SELECTED BY THE WORKING GROUP IN THE FIRST STAGE OF THE PROCESS, IN GENERAL PART OF THAT GOAL IS TO MAKE SURE THAT YOU REVIEW A REASONABLE NUMBER OF APPLICATIONS. LET'S SAY OUT OF THE 300, YOU ONLY
15 16 17 18 19 20 21	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE NOT SELECTED BY THE WORKING GROUP IN THE FIRST STAGE OF THE PROCESS, IN GENERAL PART OF THAT GOAL IS TO MAKE SURE THAT YOU REVIEW A REASONABLE NUMBER OF APPLICATIONS. LET'S SAY OUT OF THE 300, YOU ONLY GET 40 THAT HAVE BEEN SELECTED THROUGH THE FIRST
15 16 17 18 19 20 21	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE NOT SELECTED BY THE WORKING GROUP IN THE FIRST STAGE OF THE PROCESS, IN GENERAL PART OF THAT GOAL IS TO MAKE SURE THAT YOU REVIEW A REASONABLE NUMBER OF APPLICATIONS. LET'S SAY OUT OF THE 300, YOU ONLY GET 40 THAT HAVE BEEN SELECTED THROUGH THE FIRST STAGE OF THE PROCESS THAT ALLOWS US TO MAXIMIZE THE
15 16 17 18 19 20 21 22	POINTS OF CLARIFICATION. SO IN ASKING FOR BASICALLY THE TEAM TO BE ABLE TO ADD APPLICATIONS THAT WERE NOT SELECTED BY THE WORKING GROUP IN THE FIRST STAGE OF THE PROCESS, IN GENERAL PART OF THAT GOAL IS TO MAKE SURE THAT YOU REVIEW A REASONABLE NUMBER OF APPLICATIONS. LET'S SAY OUT OF THE 300, YOU ONLY GET 40 THAT HAVE BEEN SELECTED THROUGH THE FIRST STAGE OF THE PROCESS THAT ALLOWS US TO MAXIMIZE THE UTILITY OF CONVENING A WORKING GROUP AND REVIEWING.

1	COULD REASONABLY COMFORTABLY DO, BUT WE'RE ALWAYS
2	TAKING ADVANTAGE OF HAVING TO CONVENE THE REVIEW
3	GROUP. THAT'S GENERALLY HOW YOU'RE VISUALIZING THE
4	PURPOSE OF THAT DELEGATION OF AUTHORITY?
5	DR. MILLS: YEAH. AND TO MAKE SURE THAT
6	IF THERE'S SOMETHING THAT WE THINK IS REALLY
7	INTERESTING THAT NO ONE POSITIVELY SELECTED UP, WE
8	CAN ALSO CALL THAT UP TO BE REVIEWED, NOT TO BE
9	SELECTED, JUST TO BE REVIEWED.
10	CHAIRMAN SHEEHY: AND THEN FOR THE
11	CHALLENGE GRANT, I THINK THAT MAKES SENSE, BUT
12	THERE'S A DEFINED SET OF MONEY. YOU'LL COME BACK TO
13	US FOR MORE MONEY ONCE WE HIT THAT THRESHOLD?
14	DR. MILLS: SO THE IDEA IS WE WILL COME
15	BACK EVERY YEAR AND HAVE THE BOARD CHANGE AND ADJUST
16	FUNDING RATIOS FOR ALL OF THE PROGRAMS: DISCOVERY,
17	TRANSLATION, CLINICAL, EDUCATION, AND FACILITIES.
18	CHAIRMAN SHEEHY: BECAUSE THE 45 MILLION,
19	AND I'M JUST TRYING TO LINE IT OUT I HAD THAT IN
20	FRONT OF ME A MINUTE AGO. OF COURSE, I LOST IT.
21	WHAT THE EXACT NUMBERS ARE. SO IT'S 5 MILLION FOR
22	INCEPTION FOR ABOUT 20 AWARDS, ABOUT 150,000 APIECE,
23	40 MILLION FOR 35 MILLION FOR 1
24	DR. OLSON: FOR QUEST.
25	CHAIRMAN SHEEHY: FOR QUEST WHICH IS ABOUT
	40
	48

	-
1	HOW MANY AWARDS?
2	DR. OLSON: DEPENDS ON WHAT KIND OF AWARDS
3	WE GET. IT'S ANYWHERE FROM 15 TO 30.
4	CHAIRMAN SHEEHY: AND THEN YOU BASICALLY
5	HAVE 4 MILLION SET ASIDE FOR CHALLENGE.
6	DR. MILLS: IF WE HAVE ANY WE WANT TO ASK.
7	CHAIRMAN SHEEHY: SO WHEN WE PRESENT THIS
8	TO THE BOARD, COULD YOU ACTUALLY BREAK THAT OUT ON A
9	SLIDE SO WE CAN BE VERY CLEAR?
10	DR. SHEPARD: SURE.
11	CHAIRMAN SHEEHY: AND THEN, AT LEAST FOR
12	ME, I GUESS, FIRST, SHALL WE TAKE A MOTION ON THE
13	CONCEPT, AND THEN COME BACK AND DO THE MOTION FOR
14	THE FUNDING AS DR. FRIEDMAN HAS SUGGESTED? HOWEVER,
15	I THINK IN BOTH MOTIONS, I THINK I WOULD LIKE TO
16	HAVE FOR ME PERSONALLY IT WOULD BE IDEAL IF THE
17	ENRICHMENT SUPPLEMENTS, THE FUNDING FOR THAT, WAS
18	ACTUALLY MOVED INTO IT'S ELIMINATED FROM THE
19	CONCEPT, AND THAT THE FUNDING FOR THAT GETS MOVED
20	INTO THE OVERALL FUNDING FOR THE PROGRAM. IF PEOPLE
21	HAVE A VIEW THAT THEY PREFER TO HAVE MORE INCEPTION
22	BECAUSE THAT WOULD PROBABLY PAY FOR ABOUT THREE
23	INCEPTION. ANYWAY
24	MR. TORRES: IS THAT A MOTION?
25	CHAIRMAN SHEEHY: BEFORE THAT, I JUST WANT
	49
	1

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	TO MAKE SURE OTHER FOLKS, IF THEY HAVE QUESTIONS
2	BECAUSE WE'VE GONE THROUGH A LOT HERE, IF THERE'S
3	ANY QUESTIONS OR COMMENTS PEOPLE WANT TO MAKE BEFORE
4	WE START TAKING MOTIONS.
5	NOT HEARING ANY QUESTIONS, I THINK I'LL GO
6	AHEAD AND MAKE THE MOTION ON THE CONCEPT TO ADOPT
7	THE CONCEPT MINUS THE ENRICHMENT PROGRAM.
8	MR. TORRES: MINUS TO INCLUDE IT IN THE
9	OVERALL PROGRAM IS WHAT YOU MEANT?
10	CHAIRMAN SHEEHY: NO. THE CONCEPT WITHOUT
11	THE ENRICHMENT PROGRAM.
12	MR. TORRES: SO THE 700,000 STAYS WHERE?
13	CHAIRMAN SHEEHY: WELL, WE'LL TALK ABOUT
14	MONEY NEXT. SO WE'RE DOING, PER DR. FRIEDMAN, THE
15	FIRST DISCUSSION IS JUST ON THE CONCEPT THAT'S BEEN
16	PRESENTED. AND SO THAT ELEMENT OF THE CONCEPT, AT
17	LEAST FOR ME, UNLESS SOME PEOPLE HAVE OTHER
18	OPINIONS, MY MOTION WOULD BE TO APPROVE THE CONCEPT.
19	MAYBE WE SHOULD GO BACK TO THE OTHER SLIDE WHICH
20	IS
21	MR. TORRES: I'LL MAKE THE MOTION FOR YOU
22	SINCE THE CHAIR CAN'T REALLY MAKE A MOTION. I WILL
23	MOVE TO
24	DR. FRIEDMAN: SECOND.
25	MR. TORRES: OKAY. GREAT. FASTER THAN
	50

1	ME. THAT REALLY WAS.
2	CHAIRMAN SHEEHY: SO DO WE HAVE PUBLIC
3	COMMENT HERE IN SAN FRANCISCO? PUBLIC COMMENT IN
4	DUARTE?
5	DR. CHIU: YES, PUBLIC COMMENT. THIS IS
6	ARLENE CHIU. I HAVE A COUPLE OF THOUGHTS ABOUT THE
7	MATERIAL PRESENTED THUS FAR.
8	NO. 1, IT JUST OCCURRED TO ME THAT IF
9	YOU'RE EXPECTING 300 APPLICATIONS FOR INCEPTION PER
10	YEAR, AND YOU HAVE ONE OFFERING PER YEAR, AS I
11	UNDERSTOOD THE MATERIAL PRESENTED, AND YOU PLAN TO
12	FUND 20, THAT WOULD BE AROUND A 6.6 PERCENT SUCCESS
13	RATE FOR AN AWARD OF A HUNDRED FIFTY K. AND THAT
14	SEEMS TO ME A LITTLE BIT MEAGER AND THAT THERE WON'T
15	BE MANY ROUNDS PER YEAR. IS THAT CORRECT? ONE
16	ROUND PER YEAR FOR ANY OF THESE NEW IDEAS COMING
17	THROUGH WHICH EVENTUALLY WILL FEED THE PIPELINE.
18	THAT'S MY FIRST THOUGHT.
19	THE SECOND THOUGHT IS THAT AND I AGREE
20	THAT THE ENRICHMENT IDEA IS A LITTLE BIT CONFUSING
21	BECAUSE WHILE \$5,000 IS GREAT FOR A GRADUATE
22	STUDENT, A POST-DOC TO TRAVEL, IF THAT IS THE
23	INTENT, PERHAPS IT COULD BE A SEPARATE PROGRAM THAT
24	COULD HAVE A LOVELY NAME LIKE A CIRM SPECIAL AWARD
25	THAT PEOPLE CAN PUT INTO THEIR CV'S IF THEY GET

1	AWARDED SUCH A THING WITH THE SAME INTENT, BUT OPEN
2	TO A LITTLE BIT MORE PEOPLE WORKING ON CIRM GRANTS
3	PERHAPS.
4	MY THIRD THOUGHT IS ABOUT THE PROGRESSION
5	EVENTS THAT SUPPORT ADDITIONAL FUNDING. THE
6	REQUIREMENT THAT ADDITIONAL FUNDING HAS TO BE
7	ACQUIRED FIRST TO SUPPORT FURTHER DEVELOPMENT SORT
8	OF IS PUZZLING. I HEAR THAT THIS IS A REAL PROBLEM
9	OF PEOPLE HANDING OFF TO THE NEXT STAGE, AND I
10	REALLY AM GLAD THAT THERE WILL BE INCENTIVES FOR
11	THAT. HOWEVER, I WONDER IF THIS IS THE APPROPRIATE
12	SOLUTION TO THAT QUESTION. AND THAT IS THAT IF THEY
13	HAVE ALREADY BEEN FORWARD THINKING AND OUTREACHING
14	ENOUGH TO GET ADDITIONAL FUNDING FROM THE NIH, WHICH
15	TAKES ABOUT A YEAR, THEN THEY ARE REALLY QUITE FAR
16	ALONG. BUT IF YOU WANTED TO INCENTIVIZE THEM TO
17	REACH OUT, PERHAPS SOMETHING BEFORE THIS EVENT HAS
18	BEEN REACHED MIGHT DRAW MIGHT BE THE HONEY TO
19	DRAW MORE FLIES IF THEY WANT TO DO THAT.
20	AND FOLLOWING UP ON THAT QUESTION, WHAT IF
21	THE TEAM WANTS TO HAND OFF TO A COLLABORATING GROUP
22	THAT IS NOT BASED IN CALIFORNIA? IS THAT AN
23	ACCEPTABLE PARTNER TO GET AN INCENTIVE OR A
24	PROGRESSION AWARD?
25	SO THOSE ARE MY QUESTIONS TO THE
	בי

1	BOARD TO THE COMMITTEE. THANK YOU.
2	DR. OLSON: I'LL ANSWER THE LAST ONE
3	FIRST. IF THEY HAND OFF TO SOMEONE WHO WILL DEVELOP
4	IT, IRRESPECTIVE OF WHETHER THEY'RE IN CALIFORNIA OR
5	NOT, GREAT. THERE'S NO LIMITATION ON THAT.
6	THE OTHER QUESTION THAT AT LEAST I WAS
7	CLEAR ON WAS THE INCEPTION AWARD. INCEPTION AWARD
8	IS SORT OF THE VERY NEW IDEA. IT IS OFFERED ONCE A
9	YEAR. THAT IS CORRECT. THE WORKHORSE DISCOVERY
10	AWARD, THE QUEST AWARDS, IS EVERY SIX MONTHS. SO
11	THAT IS CORRECT THERE.
12	AND I AM NOT QUITE
13	CHAIRMAN SHEEHY: OKAY. THE OTHER THING
14	IS ON YOUR OTHER QUESTION ABOUT THE LOW SUCCESS RATE
15	FOR INCEPTION. THERE'S ALWAYS A POSSIBILITY FOR A
16	MEMBER OF THE COMMITTEE TO MOVE TO AS WE MOVE
17	INTO THE FUNDING DISCUSSION, EITHER MOVE ALLOCATION
18	AROUND OR ACTUALLY REQUEST HIGHER AMOUNT OF FUNDING.
19	SO THAT IS OUT THERE IF SOMEONE WANTS TO DO THAT.
20	BUT I THINK WE HAVE THIS MOTION ON THE
21	FLOOR, WHICH IS FOR THE CONCEPT. WE'VE TAKEN PUBLIC
22	COMMENT, I THINK, AND WE'VE HAD A NICE DISCUSSION.
23	MARIA, COULD YOU CALL THE ROLL PLEASE.
24	MS. BONNEVILLE: JEFF SHEEHY.
25	MR. SHEEHY: YES.

1	MS. BONNEVILLE: OS STEWARD.
2	DR. STEWARD: YEAH. I'M HERE. I'M GOING
3	TO ABSTAIN. AND REALLY THAT'S JUST TO SIGNAL THAT I
4	STILL HAVE SOME QUESTIONS ABOUT THE DETAILS, NOT
5	THAT I DON'T APPROVE OF THE CONCEPT.
6	MS. BONNEVILLE: MICHAEL FRIEDMAN.
7	DR. FRIEDMAN: YES.
8	MS. BONNEVILLE: DAVID HIGGINS.
9	DR. HIGGINS: YES.
10	MS. BONNEVILLE: BERT LUBIN.
11	DR. LUBIN: YES.
12	MS. BONNEVILLE: SHLOMO MELMED. ART
13	TORRES.
14	MR. TORRES: AYE.
15	MS. BONNEVILLE: JONATHAN THOMAS.
16	CHAIRMAN THOMAS: YES.
17	CHAIRMAN SHEEHY: THE MOTION PASSES.
18	NOW I THINK THE NEXT MOTION I WOULD
19	TAKE SO DO PEOPLE WANT TO TALK ABOUT ADJUSTING
20	ANY OF THE NUMBERS WITHIN THIS OR MAYBE ADDING TO
21	THIS? I DO THINK I WOULD HOPE THAT WE'D HAVE A
22	MOTION THAT WOULD REALIGN THE .7
23	DR. MELMED: SORRY. I WAS CUT OFF DURING
24	THE VOTING. I VOTED YES.
25	MS. BONNEVILLE: THANK YOU.
	E 4
	54

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CHAIRMAN SHEEHY: I WOULD BE VERY
2	COMFORTABLE IF THERE WAS A MOTION THAT MOVED THE .7
3	MILLION FOR ENRICHMENT INTO, I THINK, FUNDING FOR
4	INCEPTION BECAUSE THAT'S WHERE
5	MR. TORRES: SO MOVED.
6	CHAIRMAN SHEEHY: WE HAVE A SECOND FOR
7	THAT?
8	DR. FRIEDMAN: SECOND.
9	CHAIRMAN SHEEHY: OKAY. ARE PEOPLE
10	COMFORTABLE WITH THE FUNDING AMOUNTS? IS THERE ANY
11	NEED TO INSERT MORE OR REALIGN? IF THERE'S NOT,
12	OKAY. SO DO WE HAVE, FIRST OF ALL, ANY PUBLIC
13	COMMENT HERE IN SAN FRANCISCO? ANY PUBLIC COMMENT
14	IN DUARTE? NO. THEN, MS. BONNEVILLE, CAN WE PLEASE
15	CALL THE ROLL.
16	MS. BONNEVILLE: JEFF SHEEHY.
17	MR. SHEEHY: YES.
18	MS. BONNEVILLE: OS STEWARD.
19	DR. STEWARD: YES.
20	MS. BONNEVILLE: MICHAEL FRIEDMAN.
21	DR. FRIEDMAN: YES.
22	MS. BONNEVILLE: DAVID HIGGINS.
23	DR. HIGGINS: YES.
24	MS. BONNEVILLE: BERT LUBIN.
25	DR. LUBIN: YES.
	55
	JJ

1	MS. BONNEVILLE: SHLOMO MELMED.
2	DR. MELMED: YES.
3	MS. BONNEVILLE: ART TORRES.
4	MR. TORRES: AYE.
5	MS. BONNEVILLE: JONATHAN THOMAS.
6	CHAIRMAN THOMAS: YES.
7	CHAIRMAN SHEEHY: SO THE MOTION CARRIES.
8	NOW I THINK WE'RE READY TO LOOK AT THE
9	TRANSLATION STAGE FUNDING OPPORTUNITY.
10	DR. SHEPARD: OKAY. SO THANK YOU,
11	EVERYBODY.
12	SO FOR THE TRANSLATION STAGE PROGRAM, WHAT
13	WE'RE PROPOSING IS FOUR PROGRAM ANNOUNCEMENTS.
14	RATHER THAN BEING DIFFERENT TYPES OF AWARDS AS I
15	DESCRIBED FOR DISCOVERY, THESE ARE FOUR DIFFERENT
16	PROGRAMS WHERE THE OUTCOME OF EACH IS A DIFFERENT
17	TYPE OF PRODUCT. SO 15-10 IS FOR EARLY DEVELOPMENT
18	OF A THERAPEUTIC. 15-11 IS FOR EARLY DEVELOPMENT OF
19	A DIAGNOSTIC TEST, 15-12 OF A DEVICE, AND 15-13 FOR
20	A TOOL.
21	SO A GENERAL OVERVIEW OF THESE PROGRAMS,
22	AND I'LL GO WITH THE ONE SLIDE THAT COVERS ALL FOUR,
23	IS THAT LIKE OUR DISCOVERY PROGRAM, THE OUTCOME OF
24	THE TRANSLATIONAL STAGE PROGRAM WILL LEAD TO THE
25	NEXT STAGE OF DEVELOPMENT. SO IN THE CASE OF THE
	56

1	THERAPEUTIC, 15-10, THE DEVICE, THE NEXT STAGE OF A
2	SUCCESSFUL TRANSLATION GRANT WOULD BE THE ENTRY
3	CRITERIA FOR OUR CLINICAL PHASE PROGRAM, PA 15-01.
4	FOR THE DIAGNOSTIC TEST, TOOLS, THE
5	TRANSLATION PATHWAY IS A LITTLE BIT DIFFERENT. IN
6	MANY CASES THOSE PARTICULAR PRODUCTS ARE READY FOR
7	COMMERCIALIZATION OR BROAD USE IMMEDIATELY AFTER
8	TRANSLATION AND DON'T HAVE TO GO THROUGH QUITE THE
9	SAME TYPE OF DEVELOPMENT. SO THAT EXPLAINS WHY
10	THOSE OUTCOMES ARE A LITTLE BIT DIFFERENT.
11	WE DID PROPOSE AN ENRICHMENT ACTIVITY FOR
12	THOSE PROGRAMS AS WELL. I PRESUME THE DISCUSSION IS
13	GOING TO GO SIMILARLY FOR THIS, SO I'M NOT GOING TO
14	SPEND ANY TIME ON THAT.
15	JUST TO GIVE YOU A LITTLE BIT MORE DETAIL
16	ABOUT THE FOUR PROGRAMS, WE'RE PROPOSING DIRECT
17	PROJECT COSTS UP TO 5 MILLION FOR THERAPEUTICS THAT
18	TRANSLATE INTO CELL THERAPY CANDIDATES AND 2.5
19	MILLION FOR A SMALL MOLECULE CANDIDATE. SO THE
20	PROJECT TERM IS UP TO 30 MONTHS WITH ADEQUATE
21	JUSTIFICATION.
22	FOR ALL THREE OF THE OTHER TYPES OF
23	PRODUCTS, THE PROJECT TERM IS UP TO 24 MONTHS WITH
24	ADEQUATE JUSTIFICATION AND WITH DIRECT PROJECT COSTS
25	OF 1.2 MILLION FOR TRANSLATING A DIAGNOSTIC TEST, 2
	r-7

1	MILLION FOR A DEVICE, AND 1 MILLION FOR A TOOL.
2	THESE DIFFERENCES JUST REFLECT THE
3	DIFFERENT TYPES OF ACTIVITIES THAT ARE NECESSARY TO
4	UNDERTAKE IN ORDER TO COMPLETE TRANSLATION OF THOSE
5	DIFFERENT TYPES OF OUTCOMES.
6	SO OUR REQUESTED ALLOCATION I'M SORRY.
7	ARE THERE ANY QUESTIONS ON THIS PROGRAM BEFORE I GO
8	INTO THE FUNDING ALLOCATION REQUEST?
9	CHAIRMAN SHEEHY: SO I JUST HAVE ONE
10	QUESTION. SO WHEN THESE APPLICATIONS COME IN, THEY
11	CAN BE IN ANY NUMBER ACROSS THE ENTIRE RANGE. SO
12	YOU'RE NOT THERE'S NO INTENT TO SPECIFY X NUMBER
13	OF THERAPEUTICS OR X NUMBER? OKAY. GREAT.
14	AND THEN THE OTHER QUESTION. IT WILL BE
15	WHATEVER COMES UP. AND IF WE EXCEED THE AMOUNT, THE
16	PRIOR SO ALL THE SAME REVIEW PROCESS THAT WAS
17	DESCRIBED IN THE APPENDIX THAT WE BASICALLY APPROVED
18	WITH THE DISCOVERY PROJECT APPLIES HERE, RIGHT, ONE
19	TO A HUNDRED. IF THERE'S AN EXCESS OF APPLICATIONS,
20	THEN THERE WILL BE THE POSITIVE SELECTION PROCESS.
21	DR. SHEPARD: CORRECT. WE DON'T EXPECT
22	THERE TO BE AN EXCESS, BUT IF THERE ARE, WE WOULD
23	IMPLEMENT THAT PROCESS.
24	CHAIRMAN SHEEHY: AND THIS CALL WILL GO
25	OUT HOW MANY TIMES A YEAR?

	DARRISTERS REFORTING SERVICE
1	DR. SHEPARD: TWICE A YEAR.
2	CHAIRMAN SHEEHY: TWICE A YEAR.
3	DR. SHEPARD: MY VERY LAST SLIDE IS GOING
4	TO BE THE SCHEDULE.
5	CHAIRMAN SHEEHY: GREAT. OKAY. SO,
6	AGAIN, ADHERING TO THE PROCESS WE DID BEFORE, I
7	THINK FIRST I WOULD ASK FOR A MOTION ON THE PROCESS,
8	AGAIN MINUS THE ENRICHMENT ACTIVITIES.
9	MR. TORRES: SO MOVED.
10	CHAIRMAN SHEEHY: MOVED BY SENATOR TORRES.
11	DO I HAVE A SECOND?
12	DR. FRIEDMAN: SECOND.
13	CHAIRMAN SHEEHY: WE'VE GOT A SECOND FROM
14	DR. FRIEDMAN. PUBLIC COMMENT IN SAN FRANCISCO?
15	PUBLIC COMMENT IN DUARTE? CAN WE CALL THE ROLL
16	PLEASE.
17	MS. BONNEVILLE: JEFF SHEEHY.
18	MR. SHEEHY: YES.
19	MS. BONNEVILLE: OS STEWARD. MICHAEL
20	FRIEDMAN.
21	DR. FRIEDMAN: YES.
22	MS. BONNEVILLE: DAVID HIGGINS.
23	DR. HIGGINS: YES.
24	MS. BONNEVILLE: BERT LUBIN.
25	DR. LUBIN: YES.
	59

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. BONNEVILLE: SHLOMO MELMED.
2	DR. MELMED: YES.
3	MS. BONNEVILLE: ART TORRES.
4	MR. TORRES: AYE.
5	MS. BONNEVILLE: JONATHAN THOMAS.
6	CHAIRMAN THOMAS: YES.
7	MS. BONNEVILLE: AND, OS, ARE YOU ON MUTE?
8	IF WE ARE, WE CAN'T HEAR YOU.
9	CHAIRMAN SHEEHY: OKAY. THE MOTION
10	PASSES.
11	NOW, FOR THE BUDGET WHICH IS UP TO 40
12	MILLION, AND, AGAIN, I THINK I'D TAKE A MOTION
13	MOVING THE .5 MILLION INTO YOU KNOW, THE .5
14	DOESN'T PAY FOR AN AWARD. CAN I JUST MAKE A CRAZY
15	SUGGESTION? COULD WE ALLOCATE THAT .5 MILLION FOR
16	MORE INCEPTION AWARDS BECAUSE THAT WOULD GIVE US AT
17	LEAST TWO, MAYBE THREE, THAT WOULD GIVE US THREE
18	MORE INCEPTION AWARDS AS OPPOSED TO JUST
19	DR. MILLS: REALLY LIKE TWO MORE BECAUSE
20	FULLY BURDENED THEY'RE ABOUT TWO FIFTY EACH.
21	CHAIRMAN SHEEHY: WOULD YOU MAKE THAT
22	MOTION THEN, DR. FRIEDMAN?
23	DR. FRIEDMAN: I'LL BE HAPPY TO.
24	MR. TORRES: SECOND.
25	CHAIRMAN SHEEHY: SECOND FROM SENATOR
	60

	_	Drinkes lend (CE) division delived
1	TORRES. [OO WE HAVE PUBLIC COMMENT IN SAN FRANCISCO?
2	PUBLIC COM	MMENT IN DUARTE? CAN WE CALL THE ROLL.
3		MS. BONNEVILLE: JEFF SHEEHY.
4		MR. SHEEHY: YES.
5		MS. BONNEVILLE: OS STEWARD. MICHAEL
6	FRIEDMAN.	
7		DR. FRIEDMAN: YES.
8		MS. BONNEVILLE: DAVID HIGGINS.
9		DR. HIGGINS: YES.
10		MS. BONNEVILLE: BERT LUBIN.
11		DR. LUBIN: YES.
12		MS. BONNEVILLE: SHLOMO MELMED. ART
13	TORRES.	
14		MR. TORRES: AYE.
15		MS. BONNEVILLE: JONATHAN THOMAS.
16		CHAIRMAN THOMAS: YES.
17		MS. BONNEVILLE: OS, ARE YOU ON THE LINE?
18		CHAIRMAN SHEEHY: DR. MELMED.
19		DR. STEWARD: YES. I'M HERE.
20		DR. MELMED: YES. YES.
21		MS. BONNEVILLE: OKAY. GREAT. THANK YOU.
22		CHAIRMAN SHEEHY: THAT MOTION PASSES.
23		SO NOW I THINK WE'RE TALKING ABOUT
24	BRIDGES.	
25		DR. OLSON: YES.
		61
	ĺ	O±

1	DR. SHEPARD: YES. THAT WAS JUST A
2	SUMMARY OF THE CYCLES, BUT WE ALREADY EXPLAINED THAT
3	THEY'RE GOING TO BE BIANNUAL. THANK YOU.
4	CHAIRMAN SHEEHY: THANK YOU, DR. SHEPARD.
5	THAT WAS A GREAT PRESENTATION.
6	OS, CAN WE GET YOUR VOTE FOR THE FIRST
7	FUNDING REQUEST, FOR TRANSLATION, FOR THE CONCEPT
8	FOR TRANSLATION?
9	DR. STEWARD: YES. THAT'S A YES. SORRY.
10	DR. YAFFE: MEMBERS OF THE COMMITTEE,
11	MEMBERS OF THE PUBLIC, AND TEAM CIRM, I WANT TO
12	INTRODUCE THE PROPOSAL FOR THE CONCEPT FOR BRIDGES
13	2.0, A REIMAGINED INITIATIVE THAT IS SERVING CIRM'S
14	MISSION. AND I'M GOING TO TRY AND BE VERY BRIEF AND
15	WILL BE HAPPY TO TAKE QUESTIONS ABOUT DETAILS.
16	THIS PROGRAM CONTINUES OUR BRIDGES PROGRAM
17	TO FUND TRAINING FOR UNDERGRADUATE AND MASTER'S
18	LEVEL STUDENTS AND TO PREPARE CALIFORNIA'S
19	UNDERGRADUATE AND MASTER'S STUDENTS FOR HIGHLY
20	PRODUCTIVE CAREERS IN STEM CELL RESEARCH AND THERAPY
21	DEVELOPMENT.
22	IN ADDITION, WE'RE MORE CLOSELY ALIGNING
23	THE GOALS OF THIS PROGRAM WITH CIRM'S MISSION TO TRY
24	AND INSTILL PURPOSE TO THESE STUDENTS TO COMMIT MORE
25	OF THEIR ENERGY AND FOCUS AND UNDERSTANDING FOR

1	THERAPY DEVELOPMENT AND DELIVERY OF TREATMENTS TO
2	PATIENTS WITH UNMET MEDICAL NEEDS.
3	WE ARE KEEPING SOME KEY ACTIVITIES THAT
4	HAVE PROVEN VERY SUCCESSFUL IN BRIDGES 1.0. THESE
5	INCLUDE HANDS-ON RESEARCH INTERNSHIPS, A STEM CELL
6	TECHNIQUES TRAINING COURSE, EDUCATIONAL ENHANCEMENT
7	ACTIVITIES SUCH AS SEMINARS AND SPECIALIZED COURSES,
8	AND ALSO WE ARE RECOMMITTING TO A BROADENING OF
9	PARTICIPATION OF UNDERREPRESENTED POPULATIONS,
10	STUDENTS FROM UNDERREPRESENTED BACKGROUNDS
11	PARTICIPATING IN THIS PROGRAM.
12	WE ARE ADDING A NUMBER OF NEW FEATURES,
13	AGAIN, TO MORE CLOSELY ALIGN THIS PROGRAM WITH
14	CIRM'S MISSION. THE FIRST IS WE ARE ADDING AND
15	REQUIRING DIRECT PATIENT ENGAGEMENT ACTIVITIES.
16	SECOND, FORMAL TRAINING ON THE REGULATORY PATHWAY
17	AND DEVELOPMENTAL PROCESS. THIRD, COMMUNITY
18	OUTREACH AND EDUCATION ACTIVITIES, ENGAGING DIVERSE
19	CALIFORNIA COMMUNITIES, AND EDUCATING, IN FACT,
20	ENABLING BRIDGES TRAINEES TO BE AMBASSADORS TO THOSE
21	COMMUNITIES TO BRING INFORMATION ABOUT CUTTING-EDGE
22	THERAPY DEVELOPMENT AND NEW BREAKTHROUGHS IN
23	HEALTHCARE. AND FINALLY, A COMPREHENSIVE, DYNAMIC
24	ACADEMIC AND CAREER COUNSELING TO ASSIST THESE
25	TRAINEES IN FINDING POSITIONS IN JOBS IN INDUSTRY,

63

1	AT RESEARCH INSTITUTES, OR IN ACADEMIC PLANNING TO
2	PURSUE HIGHER ACADEMIC CAREERS.
3	WHO MAY APPLY? THIS PROGRAM, AS BEFORE,
4	WILL BE OPEN TO CALIFORNIA UNIVERSITIES AND COLLEGES
5	WHICH DO NOT HAVE A MAJOR STEM CELL RESEARCH
6	PROGRAM. WE FEEL THAT STUDENTS AT THE RESEARCH
7	UNIVERSITIES HAVE APPROPRIATE AND ADEQUATE ACCESS TO
8	STEM CELL RESEARCH AND NUMEROUS OPPORTUNITIES TO
9	PARTICIPATE IN THAT, BUT THIS PROGRAM, IN FACT, IS
10	TARGETED PARTICULARLY TO STUDENTS AT THE STATE
11	UNIVERSITIES, COMMUNITY COLLEGES, AND ALSO PRIVATE
12	COLLEGES IN CALIFORNIA WHO MAY NOT HAVE ACCESS AND
13	EXPOSURE TO STEM CELL RESEARCH AND CUTTING-EDGE
14	BIOMEDICAL SCIENCES.
15	THE FUNDS WILL BE AWARDED IN A SINGLE
16	REVIEW ROUND. THERE WILL BE A SINGLE APPLICATION, A
17	SINGLE REVIEW CYCLE. AND WE ARE REQUESTING THAT
18	CIRM COMMIT 45.7 MILLION TO SUPPORT UP TO 15 AWARDS.
19	EACH AWARD WILL SUPPORT UP TO TEN TRAINEES PER YEAR,
20	AND PROGRAMS WILL BE SUPPORTED UP TO FIVE YEARS WITH
21	THE CAVEAT THAT AT THE END OF THREE YEARS, ALL
22	PROGRAMS WILL BE REVIEWED, THEIR OUTCOMES ASSESSED,
23	AND ONLY THOSE PROGRAMS IN GOOD STANDING MAKING
24	PROGRESS AND DEMONSTRATING SUCCESS WILL BE FUNDED
25	FOR YEARS FOUR AND FIVE.
	C.4

SO I'LL BE HAPPY TO
CHAIRMAN SHEEHY: SO WHERE DOES THAT
THREE-YEAR REVIEW TAKE PLACE?
DR. YAFFE: WE ANTICIPATED THAT TO BE AN
INTERNAL REVIEW WITHIN CIRM. AND THOSE PROGRAMS
WILL BE CERTIFIED BY THE PRESIDENT OR HIS DESIGNEE.
DR. FRIEDMAN: MAY I ASK A CLARIFYING
QUESTION? THE \$45.7 MILLION, IS THAT THE ANNUAL
COST? IS THAT THE TOTAL FOR THE FIVE YEARS FOR ALL
THE PROGRAMS?
DR. YAFFE: THAT IS THE TOTAL FOR THE FIVE
YEARS.
DR. FRIEDMAN: IT'S LIKE \$8 MILLION A
YEAR, \$9 MILLION A YEAR. OKAY. THANK YOU.
DR. YAFFE: YES. THAT \$9 MILLION A YEAR,
ASSUMING 15 PROGRAMS WITH TEN TRAINEES PER PROGRAM.
DR. FRIEDMAN: AND ASSUMING THEY ALL
PERFORM WELL. I UNDERSTAND. THANK YOU FOR THAT
CLARIFICATION.
CHAIRMAN THOMAS: MICHAEL, ASIDE FROM THE
EXCELLENT NEW ADDITIONS TO THE PROGRAM, THE SCOPE
AND THE BUDGET AND THE NUMBER OF AWARDS ARE ROUGHLY
COMPARABLE TO WHAT WE HAD IN THE PAST ITERATION OF
THE BRIDGES PROGRAM?
DR. YAFFE: ABSOLUTELY. ACTUALLY IN TERMS
65

1	OF THE BUDGET, IT'S ALMOST IDENTICAL. WE RAISED THE
2	TUITION TO TRY AND KEEP UP WITH THE INCREASE IN
3	CALIFORNIA STATE UNIVERSITY SYSTEM TUITION. BUT
4	BEYOND THAT, THE AMOUNTS ARE ALMOST THE SAME.
5	IN TERMS OF THE SCOPE, OTHER TYPES OF
6	ACTIVITIES, THEY'RE THE SAME WITH THE EXCEPTION OF
7	THE NEW ACTIVITIES WE PUT IN.
8	MR. TORRES: I'M AN ABSOLUTELY UNABASHED
9	SUPPORTER OF THE BRIDGES PROGRAM. IN FACT, I'LL BE
10	WELCOMING THE PARTICIPANTS OF THIS LATER THIS
11	EVENING AT OUR CONFERENCE CENTER.
12	NO. 1, I WOULD LIKE TO HAVE A LITTLE MORE
13	EXPLANATION OF WHAT YOU ENVISION DIRECT PATIENT
14	ENGAGEMENT ACTIVITIES WOULD BE.
15	AND SECONDLY, I WOULD HOPE THAT YOU WOULD
16	PROVIDE FOR THE BOARD THE SUCCESS RATIO BECAUSE IT'S
17	VERY IMPRESSIVE OF WHERE THESE STUDENTS HAVE BEEN
18	PLACED AFTER THESE PROGRAMS. A LOT OF PEOPLE DON'T
19	REALIZE HOW SUCCESSFUL CIRM HAS BEEN IN PLACING
20	BRIDGES STUDENTS IN VERY HIGH CALIBER POSITIONS, NOT
21	ONLY IN CALIFORNIA, BUT ALL OVER THE COUNTRY.
22	DR. YAFFE: YES. THANK YOU, SENATOR
23	TORRES, PARTICULARLY FOR THE CALL-OUT OF THE SUCCESS
24	RATE. AND I CAN AND WILL PROVIDE THAT TO THE BOARD.
25	ROUGHLY, THE KEY NUMBERS ARE THAT 50 PERCENT OF THE

1	STUDENTS WHO COMPLETED THIS PROGRAM ARE WORKING IN
2	LABORATORIES MOSTLY IN CALIFORNIA, IN OVER 26
3	BIOTECH COMPANIES, AND IN ALL THE MAJOR RESEARCH
4	INSTITUTES AND UNIVERSITIES, AND ANOTHER 30 PERCENT
5	ARE IN GRADUATE SCHOOL OR IN M.D. PROGRAMS. BUT I
6	CAN GIVE YOU MORE DETAILS AND MORE BREAKDOWN OF
7	THAT.
8	WE ENVISION INTERACTION ACTIVITIES OR
9	ENGAGEMENT ACTIVITIES, WE WANT THE PROGRAMS WHEN
10	THEY APPLY TO PROPOSE THE ACTIVITIES. AMONG THE
11	TYPES OF ACTIVITIES, THEY COULD BE VOLUNTEER
12	SITUATIONS WHERE TRAINEES GO TO EMERGENCY ROOMS, TO
13	HOSPITALS, TO MEDICAL SETTINGS. THEY COULD BE
14	INTERACTION FORUMS WITH PATIENTS OR WITH PATIENT
15	ADVOCATES OR BOTH TO EDUCATE TRAINEES ABOUT THE
16	PATIENT'S PERSPECTIVE ON DISEASE. THEY COULD BE
17	ALSO SOME LEARNING EXPERIENCES IN TERMS OF VISITING
18	AND FINDING OUT ABOUT HEALTHCARE SETTINGS,
19	CHALLENGES TO HEALTHCARE. WE REALLY WANT THE
20	TRAINEES HERE TO APPRECIATE DISEASE FROM PATIENT'S
21	PERSPECTIVE. AND FROM THAT WE HOPE TO SEE AN
22	ENHANCED COMMITMENT TO THE GOAL OF DEVELOPING CURES
23	AND TREATMENTS FOR UNMET MEDICAL NEEDS.
24	MR. TORRES: I ALSO SEE A TREMENDOUS
25	OPPORTUNITY IN MY NEW ROLE AS A MEMBER OF THE BOARD

67

1	OF COVER CALIFORNIA FOR THIS COMMUNITY OUTREACH
2	PROVISION, PROVIDING GOOD JOINT PROGRAMS BETWEEN OUR
3	TWO AGENCIES TO REACH OUT NOT ONLY IN TERMS OF THE
4	UNDERSERVED COMMUNITY, BUT ALSO HAVING THESE YOUNG
5	PEOPLE BE ROLE MODELS IN THOSE COMMUNITIES.
6	DR. YAFFE: YES.
7	CHAIRMAN SHEEHY: SO I HAVE A COUPLE OF
8	QUESTIONS. NO. 1, I MEAN THAT 80-PERCENT SUCCESS
9	RATE, MORE GRANULARITY BECAUSE HOW MANY OF THOSE
10	JOBS THAT PEOPLE HAVE GOTTEN WERE GRANT-RELATED JOBS
11	THAT THEY LOST ONCE THE GRANT ENDED? SO THE TWO
12	EXAMPLES I HAVE OF PEOPLE I KNOW WHO WENT THROUGH
13	BRIDGES DID INDEED GET JOBS BECAUSE THEY WERE GRANTS
14	ON THE JOB. WHEN THE GRANT ENDED, THEY WERE
15	UNEMPLOYED AND THEY CONTINUED FOR A SUBSTANTIAL
16	TIME THEY CONTINUED TO BE UNEMPLOYED.
17	SO I NOTICE THAT YOU HAVE IN HERE, WHICH
18	IS A GREAT ADDITION, PROFESSIONAL AND ACADEMIC
19	COUNSELING. WILL THAT BE AVAILABLE TO PARTICIPANTS
20	THROUGHOUT THE COURSE, BOTH PEOPLE WHO PARTICIPATED
21	IN THE PAST AND FOR PEOPLE THROUGHOUT? IT'S NOT
22	LIKE YOU GET YOUR NEXT STEP AND YOU'RE KIND OF LEFT
23	ON AN ISLAND, RIGHT?
24	DR. YAFFE: WE CERTAINLY COULD ASK FOR
25	THAT TO BE AVAILABLE TO ALUMNI OF THE PROGRAM. YES.
	68

1	AND I SAY, MR. SHEEHY, WE PUT THAT ACTIVITY IN
2	PARTICULARLY BECAUSE YOU RAISED THE ISSUE PREVIOUSLY
3	WHEN WE DISCUSSED THIS ABOUT THE NEED FOR ASSISTANCE
4	FOR THESE PEOPLE.
5	IN TERMS OF HOW MANY ARE STILL EMPLOYED,
6	IT'S A DIFFICULT THING TO KNOW. THE BIOTECH
7	INDUSTRY AND THE BIOMEDICAL RESEARCH ENTERPRISE IS
8	DEPENDENT ON MONEY THAT'S NOT PERMANENT. THE GRANTS
9	COME AND GO. PROJECTS AT INDUSTRIES COME AND GO.
10	THE FEEDBACK WE RECEIVED FROM ALL OF THE DIFFERENT
11	PROGRAMS, THE 16 PROGRAMS WE'RE CURRENT SUPPORTING,
12	HAVE INDICATED A LOT OF SUCCESS IN THEIR TRAINEES
13	FINDING JOBS AND PRESUMABLY SUSTAINING JOBS. BUT I
14	THINK THAT THAT'S A VALID CONCERN. IF WE CAN ASK
15	PROGRAMS TO CONTINUE TO PROVIDE ADVISING FOR CAREERS
16	AND JOB PLACEMENT TO ALUMNI OF THE PROGRAM, I THINK
17	THAT WOULD BE AN ASSET.
18	CHAIRMAN SHEEHY: I THINK THAT MIGHT BE
19	BETTER TO BE A REQUIREMENT. AND I THINK 80 PERCENT
20	IS GOOD, BUT I'D LIKE TO SEE, AT THE AMOUNT WE'RE
21	SPENDING PER STUDENT, I'D LIKE TO SEE THAT CLOSER TO
22	A HUNDRED PERCENT.
23	DR. YAFFE: YEAH. ACTUALLY 80 PERCENT IS
24	AN UNDERESTIMATE BECAUSE IF WE LOOK AT THE REMAINING
25	20 PERCENT, HALF OF THOSE STUDENTS ARE ACTUALLY
	60

1	STILL IN THE PROGRAM BECAUSE THE PARENT PROGRAM
2	THAT'S INVOLVED IS SOMETIMES A TWO- TO THREE-YEAR
3	PROGRAM. WE ONLY FUND THEM FOR ONE YEAR OUT OF
4	THAT.
5	AND THEN SOME REMAINDER OF THE OTHERS HAVE
6	ACTUALLY GONE INTO OTHER KINDS OF PROFESSIONS, SUCH
7	AS TEACHING, GOVERNMENT SERVICE, AND OTHER THINGS
8	WHICH I THINK ARE VALID OUTCOMES. BUT I THINK YOUR
9	POINT IS ABSOLUTELY CORRECT IN THAT WE WOULD LIKE TO
10	SEE A HUNDRED PERCENT SUCCESS. WE WANT TO SEE THESE
11	TRAINEES WHO HAVE GOTTEN RAISED FROM THE LABS WHERE
12	THEY WORKED, FROM THE PI'S WHO HAVE SUPERVISED THEIR
13	WORK, THAT THEY'RE REALLY EXCEPTIONAL INDIVIDUALS,
14	BUT WE'D LIKE TO SEE THEM ALL MOVING FORWARD IN
15	ACTIVE AND PRODUCTIVE ACTIVITY.
16	CHAIRMAN SHEEHY: AND THEN I HAVE AN
17	IRRECONCILABLE DIFFERENCE WITH THE IDEA OF HAVING
18	INTERNAL REVIEW AT THREE YEARS. SO EITHER WE
19	RECOMPETE TOWARDS THE FIVE-YEAR GRANT. I JUST THINK
20	THAT THE AMOUNT OF MONEY THAT'S INVOLVED, THAT
21	THAT'S NEEDS TO GO THROUGH A COMPLETE PROCESS IF
22	THERE IS GOING TO BE A REVIEW OF THE PROGRAM. BUT I
23	DON'T I'M EXTREMELY UNCOMFORTABLE WITH AN
24	INTERNAL REVIEW FOR THAT MUCH MONEY INVOLVING THIS
25	MANY INSTITUTIONS.
	70

1	SO I DON'T KNOW WHAT THE ANSWER IS TO
2	THAT, BUT I COULD NOT SUPPORT THIS PROGRAM AS IT'S
3	CONSTRUCTED WITH THAT IN THERE. IF YOU WANTED TO DO
4	IT FOR FIVE YEARS OR IF YOU WANT TO MAKE IT A
5	THREE-YEAR PROGRAM AND THEN COME BACK, IT SHOULD BE
6	THREE, FOUR YEARS. I THINK IF YOU ARE GOING REVIEW
7	A PROGRAM, IT SHOULD GO BACK THROUGH IT SHOULD BE
8	RECOMPETED. IT SHOULD GO BACK THROUGH PEER REVIEW.
9	IF PEOPLE ARE NOT DOING WHAT THEY'RE SUPPOSED TO DO,
10	I ASSUME THAT UNDER THIS LEADERSHIP THAT THOSE
11	GRANTS WOULD BE TERMINATED ANYWAY. SO THE PURPOSE
12	OF THE REVIEW TO ME IN THREE YEARS, I'M JUST NOT
13	SUPPORTIVE OF THAT PROCESS. EITHER IT'S A FIVE-YEAR
14	GRANT
15	DR. MILLS: NO. YOUR POINT IS WELL TAKEN.
16	EITHER THEY'RE PERFORMING OR THEY'RE NOT PERFORMING.
17	IF THEY'RE NOT PERFORMING, THEY'RE GOING TO GET
18	CANCELED. IT'S JUST PART OF OUR JOB.
19	CHAIRMAN SHEEHY: SO
20	DR. MILLS: THAT'S THE FIVE-YEAR NUMBER.
21	MR. TORRES: MAKE IT FOR FIVE YEARS.
22	CHAIRMAN SHEEHY: IS THAT YOUR PREFERENCE?
23	WHATEVER. BUT I DON'T WANT PEOPLE THINKING THEY'RE
24	GOING TO BE UNDER THE GUN AT THREE YEARS. I WANT
25	PEOPLE TO DO WHAT THEY'RE SUPPOSED TO DO, AND I
	71
	/ -

1	ASSUME THEY WILL, AND WE'LL HAVE THE MANAGEMENT OF
2	THIS GRANT. BUT I DO THINK WHEN IT ENDS, NO MORE
3	ROLLOVERS. WE BRING IT BACK, WE RE-REVIEW.
4	MR. TORRES: SO MOVED.
5	CHAIRMAN THOMAS: MICHAEL, AM I INCORRECT
6	OR HAVEN'T WE HAD SOME IN THE PAST INCONSISTENCY ON
7	REPORTING AND MONITORING OF WHERE THE BRIDGES
8	STUDENTS HAVE ENDED UP BY THE DIFFERENT AWARDEES?
9	IS THAT CORRECT?
10	DR. YAFFE: WE'VE HAD A FEW PROGRAMS OUT
11	OF THE 16 THAT HAVEN'T REPORTED AS REGULARLY, BUT WE
12	WILL MAKE REPORTING REQUIREMENTS EVEN STRONGER IN
13	THIS RFA.
14	CHAIRMAN THOMAS: I GUESS MY QUESTION IS
15	IS GIVEN THERE HAVE BEEN SOME INCONSISTENCIES, HOW
16	COMFORTABLE ARE YOU WITH THOSE PERCENTAGE NUMBERS OF
17	SUCCESS THAT YOU WERE QUOTING?
18	DR. YAFFE: ACTUALLY I'M VERY COMFORTABLE
19	BECAUSE WE HAVE HAD REPORTS OF OUTCOMES FROM ALL
20	PROGRAM DIRECTORS. BUT IN ADDITION, IN PARALLEL,
21	THE STATE UNIVERSITY SYSTEM, SUSAN BAXTER IN
22	PARTICULAR WITH THE CAL STATE BIOTECH INITIATIVE, I
23	GUESS IT'S CALLED, MONITORS THE TRAINEES FROM THIS
24	PROGRAM, AT LEAST THOSE AT THE STATE UNIVERSITY,
25	WHICH ARE MOST OF OUR PROGRAMS. AND HER NUMBER IS

1	EVEN BETTER THAN THE NUMBERS THAT WE GOT FROM THE
2	PROGRAM DIRECTORS. SO I'M QUITE CONFIDENT. WE KNOW
3	WHERE OF THE ROUGHLY 700 STUDENTS WHO HAVE
4	COMPLETED THE PROGRAM, WE KNOW WHERE 650 OF THEM
5	ARE.
6	CHAIRMAN THOMAS: I WOULD JUST SUGGEST
7	THAT WE HAVE A FAIRLY STRICT MONITORING REQUIREMENT
8	FOR THOSE APPLICANTS SO WE KNOW AND KEEP TRACK OF
9	EVERYBODY.
10	DR. YAFFE: ABSOLUTELY.
11	CHAIRMAN SHEEHY: SO WITH THOSE TWO
12	FRIENDLY AMENDMENTS DID WE GET A SECOND FOR YOUR
13	MOTION?
14	MR. TORRES: NO. I'M STILL LONELY.
15	UNIDENTIFIED SPEAKER: SECOND.
16	CHAIRMAN SHEEHY: MAYBE WE CAN ADD TWO
17	FRIENDLY AMENDMENTS. ONE IS THE STRICT REQUIREMENT
18	ON REPORTING AND THE SECOND IS A REQUIREMENT ON
19	OPENING THE PROFESSIONAL DEVELOPMENT OFFICE TO
20	MAKING SURE THAT'S AVAILABLE TO ALUMNI SO IT DOESN'T
21	BECOME A ONE-OFF FOR THE PEOPLE WHO GO THROUGH OUR
22	PROGRAM HAVE A PLACE TO GO, TO TAKE THE SKILLS THAT
23	THEY'VE LEARNED THROUGH OUR PROGRAM.
24	MR. TORRES: LET ME THINK ABOUT THAT. SO
25	HOW MANY WHAT'S THE AVERAGE COST PER STUDENT PER

1	YEAR?
2	DR. YAFFE: I CAN TELL YOU THE MAXIMUM
3	COST PER STUDENT PER YEAR. THAT IS, FUNDS ARE
4	BROKEN DOWN INTO FUNDS FOR THE STUDENT AND FUNDS FOR
5	THE PROGRAM OVERALL. SO ARE YOU ASKING
6	MR. TORRES: I WANT TO BE ABLE TO SAY WHAT
7	WE ARE GIVING TO A PARTICULAR STUDENT, NOT THE
8	PROGRAM.
9	DR. YAFFE: THE MAXIMUM WE'RE GIVING TO A
10	PARTICULAR STUDENT IS \$43,500.
11	MR. TORRES: PER YEAR.
12	DR. YAFFE: PER YEAR. THAT INCLUDES
13	STIPENDS, TUITION AND FEES, RESEARCH SUPPORT, STEM
14	CELL COURSE, AND TRAVEL MONEY.
15	MR. TORRES: THAT'S INCREDIBLE. I'LL GO
16	ALONG WITH THE FRIENDLY AMENDMENTS.
17	CHAIRMAN SHEEHY: OKAY. DO WE HAVE ANY
18	OTHER DISCUSSION FROM ANYBODY ON THE PHONE? DO WE
19	HAVE PUBLIC COMMENT IN SAN FRANCISCO? PUBLIC
20	COMMENT IN DUARTE?
21	DR. CHIU: YES. THIS IS ARLENE CHIU AT
22	DUARTE. I APPLAUD THE PROGRAM IN GENERAL. I
23	JUST IT JUST OCCURRED TO ME THAT ONE OF THE MOST
24	IMPORTANT ROLES OF THE CAL STATE UNIVERSITIES IS TO
25	TRAIN THE TEACHERS IN OUR PUBLIC SCHOOLS. AND I

74

1	WONDERED IF THERE COULD BE SOMETHING ABOUT IF WE
2	TRAINED TEACHERS WHO CAN THEN TALK ABOUT STEM CELL
3	RESEARCH, ARE KNOWLEDGEABLE ABOUT STEM CELL
4	RESEARCH, AND TEACH THE NEXT GENERATION OF THE
5	PUBLIC ABOUT STEM CELL RESEARCH, THAT THAT WOULD BE
6	SOMETHING DESIRABLE.
7	MR. TORRES: THAT WOULD REQUIRE
8	LEGISLATION.
9	DR. CHIU: OH, WELL.
10	DR. YAFFE: ALTHOUGH, ARLENE, I CAN TELL
11	YOU THAT ABOUT 3 PERCENT OF THE TRAINEES ARE NOW
12	TEACHING. SO MADE PERSONAL CHOICES AFTER THEIR
13	PROGRAM.
14	MR. TORRES: THOSE ARE CURRICULA ISSUES
15	WHICH ARE UNIVERSALLY THE PURVIEW OF THE
16	LEGISLATURE.
17	DR. CHIU: I SEE. THANK YOU.
18	MR. TORRES: GIVEN TO THE ONE THAT HELPED
19	US, THE SENATOR WHO I PURPOSELY FORGET HER NAME.
20	CHAIRMAN SHEEHY: DO WE HAVE ANY MORE
21	PUBLIC COMMENT? OKAY. CAN WE CALL THE ROLL PLEASE,
22	MS. BONNEVILLE.
23	MS. BONNEVILLE: JEFF SHEEHY.
24	MR. SHEEHY: YES.
25	MS. BONNEVILLE: OS STEWARD.
	75

	D, MMIDTERS METORITING SERVICE
1	DR. STEWARD: YES.
2	MS. BONNEVILLE: MICHAEL FRIEDMAN.
3	DR. FRIEDMAN: YES.
4	MS. BONNEVILLE: DAVID HIGGINS.
5	DR. HIGGINS: YES.
6	MS. BONNEVILLE: BERT LUBIN.
7	DR. LUBIN: YES.
8	MS. BONNEVILLE: SHLOMO MELMED.
9	DR. MELMED: YES.
10	MS. BONNEVILLE: ART TORRES.
11	MR. TORRES: AYE.
12	MS. BONNEVILLE: JONATHAN THOMAS.
13	CHAIRMAN THOMAS: YES.
14	CHAIRMAN SHEEHY: SO WE'RE AT THE LIMIT OF
15	OUR TIME, BUT IF PEOPLE ARE COMFORTABLE, WE JUST
16	HAVE TWO MORE ITEMS THAT I THINK SHOULD GO THROUGH
17	AND BE FAIRLY STRAIGHTFORWARD. THE FIRST ONE IS THE
18	SPARK PROGRAM, WHICH HAS BEEN THE SUMMER PROGRAM FOR
19	KIDS IN HIGH SCHOOL. DR. VESSAL.
20	DR. VESSAL: THANK YOU, MEMBERS OF THE
21	BOARD, PUBLIC, LADIES AND GENTLEMEN. I'D LIKE TO
22	INTRODUCE THE NEW UPDATED VERSION OF WHAT WE'VE
23	KNOWN AS THE CREATIVITY AWARDS. NOW WE HAVE RENAMED
24	IT THE SPARK, WHICH STANDS FOR SUMMER PROGRAM TO
25	ACCELERATE REGENERATIVE MEDICINE KNOWLEDGE.
	76
	<i>i</i> U

76

1	SO BRIEFLY, THE OBJECTIVE OF THE PROGRAM
2	IS TO REALLY START GENERATING THE NEXT GENERATION IN
3	REGENERATIVE MEDICINE FOR HOPEFULLY THE NEXT
4	GENERATION OF SCIENTISTS. AND IT'S REALLY TO
5	INSPIRE AND TO PREPARE CALIFORNIA'S HIGH SCHOOL
6	STUDENTS IN THE FIELD OF REGENERATIVE MEDICINE AS IT
7	RELATES TO HUMAN DISEASES.
8	THE COMPONENTS THAT WE'RE KEEPING, AS WITH
9	OUR PREVIOUS PROGRAM, CREATIVITY AWARDS, ARE, OF
10	COURSE, THE FULL-TIME, HANDS-ON SUMMER INTERNSHIP AT
11	A HOST LABORATORY, WHICH IS 40 HOURS A WEEK FULL
12	TIME, AND BROADENING THEIR PARTICIPATION FROM THE
13	UNDERREPRESENTED POPULATIONS. THIS WAS REALLY ONE
14	OF THE KEY FACTORS IN OUR OLD AWARD, AND WE ARE
15	KEEPING THAT BECAUSE THAT'S BEEN REALLY ONE OF THE
16	PILLARS OF OUR MISSION HERE AS WELL. AND, OF
17	COURSE, THE END OF THE SUMMER POSTER DAY WHICH WE
18	HOST USUALLY HERE IN THE BAY AREA.
19	THE COMPONENTS THAT WE ARE ADDING TO THE
20	PROGRAM ARE DIRECT PATIENT ENGAGEMENT ACTIVITIES,
21	ONE WHICH MUST INCLUDE IN BONE MARROW BANK OR DRIVES
22	OR DONATING BLOOD. I CAN ANSWER A QUESTION ON THIS.
23	SO THE REASON FOR THIS IS THAT A LOT OF THE STUDENTS
24	COME FROM A VERY DIVERSE BACKGROUND FOR THIS
25	PROGRAM, AND WE THOUGHT THAT THIS WOULD GIVE ONE
	77

1	MORE ACTIVITY THAT WE CAN ACTUALLY SORT OF
2	CONTRIBUTE TO IN THEIR ENROLLMENT IN OUR PROGRAM
3	WITH OUR MISSION.
4	MR. TORRES: SO WHAT ARE THE LEGAL ISSUES
5	INVOLVED WHEN YOU HAVE A HIGH SCHOOL STUDENT BEING
6	AS A POTENTIAL DONOR?
7	DR. MILLS: SO ORGANIZING A DRIVE OR A
8	REGISTRY.
9	DR. VESSAL: A REGISTRY REALLY. IT WOULD
10	BE THAT KIND OF A THING.
11	MR. TORRES: SO THE SUMMER PROGRAM IS TO
12	ACCELERATE REGENERATIVE MEDICINE KNOWLEDGE. CAN WE
13	ADD YEARLY TO THAT NAME?
14	DR. VESSAL: SURE. SO THE SECOND
15	COMPONENT WE'RE ADDING IS WE ARE REQUIRING THE
16	PROGRAMS TO HAVE A PREP TRAINING COURSE PRIOR TO THE
17	COMMENCEMENT OF THE RESEARCH ACTUALLY. NOW, MOST OF
18	THE PROGRAMS ALREADY HAVE DONE THIS IN OUR OLD
19	CREATIVITY PROGRAM, BUT WE WANT TO MAKE SURE THAT
20	THEY ALL DO THIS SO THAT STUDENTS ARE PREPARED WHEN
21	THEY ACTUALLY START THEIR RESEARCH AT A HOST LAB.
22	AND THE COMMUNITY OUTREACH ACTIVITIES ARE
23	ENGAGING, AGAIN, DIVERSE CALIFORNIA COMMUNITIES VIA
24	SOCIAL MEDIA. THIS IS, AGAIN, ANOTHER COMPONENT
25	THAT WE'VE ADDED IN THE PAST TWO YEARS AS PART OF

1	THE CREATIVITY AWARDS, AND WE HAVE SEEN QUITE A HIGH
2	RATE OF SUCCESS IN BOTH THE ENGAGEMENT OF STUDENTS
3	AND THEIR WILLINGNESS TO DO THIS VIA INSTAGRAM,
4	FACEBOOK, AND WEEKLY BLOGS OF THEIR EXPERIENCES.
5	AND IT'S ALSO YIELDED ACTUALLY QUITE A THE PR IN
6	CALIFORNIA IN THEIR SMALL COMMUNITIES, IN THEIR
7	COMMUNITIES ACTUALLY BY THEIR LOCAL NEWS AGENCIES.
8	SO, AGAIN, WE ARE DEFINITELY GOING FORWARD WITH THAT
9	WITH THAT COMPONENT.
10	THE INSTITUTIONS THAT CAN APPLY ARE THE
11	CALIFORNIA UNIVERSITIES, COLLEGES, OR RESEARCH
12	INSTITUTES THAT HAVE ALREADY AN ESTABLISHED TYPE OF
13	PROGRAM, SUMMER RESEARCH PROGRAM IN PLACE. AND,
14	AGAIN, THIS WOULD BE CONSIDERED AS A SINGLE REVIEW
15	CYCLE FOR THE APPLICATION. AND WE ARE REQUESTING UP
16	TO \$4 MILLION FOR SUPPORTING UP TO TEN PROGRAMS, AND
17	EACH AWARD WILL SUPPORT A MINIMUM OF FIVE AND UP TO
18	TEN TRAINEES PER YEAR. AND, AGAIN, THE PROGRAM WILL
19	BE SUPPORTED FOR UP TO FIVE YEARS.
20	CHAIRMAN THOMAS: SO COUPLE QUESTIONS.
21	ONE, WHY ARE WE NOT ALLOWING FOR A NEW APPLICANT IF
22	THERE IS ONE THAT CAN PULL TOGETHER A PROGRAM?
23	DR. VESSAL: THAT IS ABSOLUTELY OKAY AS
24	LONG AS THEY CAN PROVIDE EVIDENCE THAT THEY ACTUALLY
25	HAVE THE SUPPORT NECESSARY FOR THIS PROGRAM.

1	PREVIOUSLY WE HAD IT THAT THEY NEEDED TO HAVE AN
2	ESTABLISHED PROGRAM ALREADY IN PLACE SO THAT WE
3	WOULD NOT BE PAYING FOR A NEW PROGRAM THROUGH SPARK
4	AND BASICALLY REINVENTING THE WHEEL.
5	CHAIRMAN THOMAS: IS THAT WHAT THAT FIRST
6	THING SAYS?
7	DR. VESSAL: ESTABLISHED HIGH SCHOOL. IT
8	DOESN'T HAVE TO BE CIRM-FUNDED THOUGH. SO WHAT
9	WE'RE DOING ACTUALLY IS THAT THIS IS ACTUALLY
10	PIGGYBACKING ON WHAT THEY ALREADY HAVE AT THE
11	INSTITUTIONS, AND WE THOUGHT, AGAIN, THIS WOULD BE
12	EASIER IN TERMS OF REALLY GETTING (INAUDIBLE).
13	CHAIRMAN THOMAS: THE SECOND QUESTION IS
14	AM I INCORRECT IN SAYING THAT CERTAIN OF OUR
15	PROGRAMS ALSO HAVE A TEN-DAY OPTION? FOR EXAMPLE,
16	WE WERE AT USC YESTERDAY FOR A PATIENT ADVOCATE TOWN
17	HALL, HAD A BUNCH OF THEIR KIDS THERE WHO WERE IN
18	THE HIGH SCHOOL PROGRAM. AND THEY WERE TALKING
19	ABOUT BOTH A SUMMER-LONG PROGRAM AND A TEN-DAY
20	OPTION. ARE WE FUNDING THE TEN-DAY OPTION?
21	DR. VESSAL: NO, WE'RE NOT. THIS WOULD BE
22	A FULL-TIME SUMMER AGAIN, EACH PROGRAM HAS A
23	DIFFERENT DURATION IN TERMS OF THEIR PROGRAMS. SO,
24	FOR INSTANCE, SANTA BARBARA HAS SIX WEEKS, AND
25	THAT'S REALLY THE LOWEST NUMBER THAT I'VE SEEN, BUT
	00

1	THEY ARE VERY SUCCESSFUL AT WHAT THEY DO. GENERALLY
2	SPEAKING, THEY AVERAGE 10 TO 12 WEEKS, BUT WE ARE
3	NOT DOING THE TEN DAYS.
4	CHAIRMAN THOMAS: OKAY. ASK THEM HOW
5	THEY'RE GETTING THAT FUNDED BECAUSE THAT WAS AN
6	INTERESTING OPTION WHICH ACTUALLY IS SOMETHING THAT
7	DOES MAKE SOME SENSE BECAUSE THERE ARE A NUMBER OF
8	KIDS WHO MAY NOT HAVE THAT LONG A TIME AVAILABLE
9	DURING THE SUMMER DUE TO OTHER COMMITMENTS.
10	DR. VESSAL: SURE. IT'S JUST THAT IT'S A
11	CONCERN THERE WOULD BE, I WOULD THINK, IT WOULDN'T
12	BE SUFFICIENT AMOUNT OF TIME. AS IT IS, THE TWO
13	MONTHS, THE THREE MONTHS WOULD BE A REALLY CONDENSED
14	TIME TO REALLY GET ANYTHING REALISTIC IN A REALISTIC
15	WAY AND TO LEARN ANYTHING TO GET AN ACTUAL
16	EXPERIENCE OUT OF IT. SO I FEEL IF THEY HAVE TEN
17	DAYS
18	CHAIRMAN THOMAS: I WOULD RECOMMEND TO YOU
19	IT WOULD BE WORTH HEARING WHAT THEY DO.
20	DR. VESSAL: SURE.
21	CHAIRMAN THOMAS: VICKI FOX AT USC IS THE
22	OPERATIVE PERSON. YOU MIGHT JUST GIVE
23	DR. VESSAL: I'LL DEFINITELY CONTACT THEM.
24	ABSOLUTELY. SURE.
25	CHAIRMAN SHEEHY: SO DO WE HAVE QUESTIONS
	01
	81

1	FROM OTHER MEMBERS OF THE BOARD? WE HAVE PUBLIC
2	COMMENT IN SAN FRANCISCO? PUBLIC COMMENT IN DUARTE?
3	DR. VESSAL: SO ONE MORE THING THAT I'D
4	LIKE TO ADD HERE IS THAT, AGAIN, AS WITH THE BRIDGES
5	PROGRAM, THIS WAS ALSO CONSTRUCTED IN A WAY THAT
6	YEARS FOUR AND FIVE WERE BASED ON THE CONDUCT OF THE
7	PROGRAM AND AS SUCH THEN INTERNALLY ON HOW THIS
8	PROGRAM HAS RUN AND THEN BASED ON CONTINUING WITH
9	YEARS FOUR AND FIVE. SO I JUST DON'T KNOW WHERE YOU
10	STAND.
11	CHAIRMAN SHEEHY: I THINK I WOULD HAVE THE
12	SAME CONCERN. SO CAN WE GET A MOTION WITH THAT
13	AMENDMENT?
14	DR. HIGGINS: MOVE IT.
15	MR. TORRES: SECOND.
16	CHAIRMAN SHEEHY: SO MOVED BY SENATOR
17	TORRES, SECONDED BY DAVID HIGGINS.
18	CHAIRMAN THOMAS: OTHER WAY AROUND.
19	CHAIRMAN SHEEHY: OTHER WAY AROUND. OKAY.
20	SO CAN WE CALL THE ROLL.
21	MS. BONNEVILLE: JEFF SHEEHY.
22	MR. SHEEHY: YES.
23	MS. BONNEVILLE: OS STEWARD.
24	DR. STEWARD: YES.
25	MS. BONNEVILLE: MICHAEL FRIEDMAN.
	82
	02

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	DR. FRIEDMAN: YES.
2	MS. BONNEVILLE: DAVID HIGGINS.
3	DR. HIGGINS: YES.
4	MS. BONNEVILLE: BERT LUBIN.
5	DR. LUBIN: YES.
6	MS. BONNEVILLE: SHLOMO MELMED.
7	DR. MELMED: YES.
8	MS. BONNEVILLE: ART TORRES.
9	MR. TORRES: AYE.
10	MS. BONNEVILLE: JONATHAN THOMAS.
11	CHAIRMAN THOMAS: YES.
12	CHAIRMAN SHEEHY: THE MOTION PASSES. SO
13	DO WE WANT TO DO THE LAST THING ON THE AGENDA, WHICH
14	IS A MEMORANDUM FROM DR. SAMBRANO ON UPDATES TO
15	CLINICAL PROGRAM ANNOUNCEMENTS.
16	DR. SAMBRANO: OKAY. THANK YOU. THIS IS
17	GIL. I WANT TO BRING FOR YOUR CONSIDERATION
18	PROPOSED UPDATES TO THE CLINICAL PROGRAM
19	ANNOUNCEMENTS. TO BE BRIEF, WE EXPECTED THAT AT
20	SOME POINT AFTER WE LAUNCHED THE CIRM 2.0 CLINICAL
21	PROGRAM, THROUGH ITS IMPLEMENTATION, WE LEARNED
22	QUITE A BIT AND NEED TO COME BACK TO YOU WITH SOME
23	TWEAKS FOR THE PROGRAM. SO THERE ARE FIVE PROPOSED
24	CHANGES WHICH WE ARE BRINGING TO YOU WE'D LIKE TO
25	INCORPORATE INTO THE PROGRAM ANNOUNCEMENTS OF 15-01
	83

1	THROUGH 15-03. AND, IN ADDITION, WE'D LIKE TO
2	REQUEST AN ALLOCATION OF 100 MILLION TO ISSUE NEW
3	AWARDS UNDER THAT CLINICAL PROGRAM DURING THE FISCAL
4	YEAR 2015 TO 2016.
5	I HAD A COUPLE OF SLIDES, BUT I'M NOT
6	GOING TO GO THROUGH THEM. THEY ARE BASICALLY
7	SUMMARIZED IN THE MEMO. SO IF YOU HAVE ANY
8	QUESTIONS, I'D BE HAPPY TO ADDRESS THEM.
9	CHAIRMAN SHEEHY: SO DOES ANYBODY HAVE ANY
10	QUESTIONS ABOUT THIS PROPOSAL? DO WE HAVE A MOTION
11	TO ADOPT?
12	MR. TORRES: YES. I MOVE TO ADOPT THE
13	MOTION BECAUSE I NEVER HAD THIS OPPORTUNITY IN 20
14	YEARS IN THE LEGISLATURE TO MAKE A MOTION FOR \$100
15	MILLION. UNBELIEVABLE.
16	CHAIRMAN SHEEHY: DO I HAVE A SECOND?
17	DR. HIGGINS: SECOND.
18	CHAIRMAN SHEEHY: SECOND FROM DAVID
19	HIGGINS. DO WE HAVE ANY COMMENTS HERE IN SAN
20	FRANCISCO? ANY PUBLIC COMMENT IN DUARTE? THEN
21	COULD WE CALL THE ROLL?
22	MS. BONNEVILLE: JEFF SHEEHY.
23	MR. SHEEHY: YES.
24	MS. BONNEVILLE: OS STEWARD.
25	DR. STEWARD: YES.
	84

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

```
1
                MS. BONNEVILLE: MICHAEL FRIEDMAN.
 2
                DR. FRIEDMAN: YES.
 3
                MS. BONNEVILLE: DAVID HIGGINS.
 4
                DR. HIGGINS: YES.
 5
                MS. BONNEVILLE: BERT LUBIN.
 6
                DR. LUBIN: YES.
 7
                MS. BONNEVILLE: SHLOMO MELMED. ART
 8
     TORRES.
 9
                MR. TORRES: AYE.
10
                MS. BONNEVILLE: JONATHAN THOMAS.
11
                CHAIRMAN THOMAS: YES.
12
                MS. BONNEVILLE: DR. MELMED, ARE YOU ON
13
     THE LINE?
14
                DR. MELMED: I SAID YES. YES.
15
                MS. BONNEVILLE: THANK YOU.
16
                CHAIRMAN SHEEHY: SO THE MOTION CARRIES.
     IF THERE'S NOTHING ELSE, THEN I THINK I'M READY TO
17
     ADJOURN THE MEETING. THANK YOU EVERYONE AND THANK
18
19
     YOU TO THE CIRM TEAM FOR THEIR HARD WORK.
20
                     (APPLAUSE.)
21
                     (THE MEETING WAS THEN CONCLUDED AT
22
     3:46 P
23
                     .)
24
25
                               85
```

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	
2	
3	
4	REPORTER'S CERTIFICATE
5	
6	
7	
8	I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT
9	THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE SCIENCE SUBCOMMITTEE OF THE
10	INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN
11	THE MATTER OF ITS REGULAR MEETING HELD ON JULY 15, 2015, WAS HELD AS HEREIN APPEARS AND THAT THIS IS
12	THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE
13	REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE
14	AND ACCURATE RECORD OF THE PROCEEDING.
15	
16	
17	BETH C. DRAIN, CSR 7152 BARRISTERS' REPORTING SERVICE
18	160 S. OLD SPRINGS ROAD SUITE 270 ANAHEIM, CALIFORNIA (714) 444-4100
19	
20	
21	
22	
23	
24	
25	
	86